Protocol C3300-102 
1 TITLE PAGE 
Protocol Title
: A Phase 1 Placebo -controlled Study of the Safety and 
Tolerability of Rectally Administered, Multiple -ascending 
Doses of IW -3300 in Healthy Subjects 
Short Title:  A Phase 1 Study of Multiple- ascending Doses of IW-3300 in 
Healthy Subjects  
Protocol Number: C3300-102 
Version Number : Version 1 
Final Date:  14 February 2022 
Study Intervention: IW‑3300 
Study Phase : 1 
Sponsor:  Ironwood Pharmaceuticals, Inc. 
100 Summer Street, Suite 2300 Boston, MA 02110 USA  
Medical Monitor Study Contact : Medical m onitor and study contact information will be 
provided separately.  
Confidentiality Statement 
The contents of this document are confidential and belong to Ironwood Pharmaceuticals, Inc. 
Except as may be otherwise agreed to in writing, by accepting or reviewing these materials, you 
(including any colleagues or subordinates) agree to hold such information in confidence and not 
to disclose it to others (except where req uired by applicable law), nor to use it for unauthorized 
purposes. In the event of actual or suspected breach of this obligation, Ironwood should be 
promptly notified. 
Protocol C3300-102 
2 TABLE OF CONTENTS  
TITLE PAGE ...................................................................................................................................1  
1. PROTOCOL SUMMARY  ............................................................................................8  
1.1. Synopsis ........................................................................................................................8  
Protocol Title  ................................................................................................................ 8 
Short Title  .....................................................................................................................8  
Rationale .......................................................................................................................8  
Objectives and Endpoints .............................................................................................8  
Over all Design  ..............................................................................................................9  
Disclosure Stat ement  ....................................................................................................9  
Number of Subjects ......................................................................................................9  
Intervention Groups and Duration ................................................................................9  
Data Monitorin g Committee: No  ................................................................................10  
1.2. Schema  ........................................................................................................................10  
1.3. Schedule of Activities  .................................................................................................11  
2. INTRODUCTION  ......................................................................................................15  
2.1. Study Rationale ...........................................................................................................15  
2.2. Background .................................................................................................................15  
2.3. Benefit/Risk Assessment  ............................................................................................17  
2.3.1.  Risk Assessment  .........................................................................................................17  
2.3.2.  Benefit Assessment  .....................................................................................................18  
2.3.3.  Overall Benefit: Risk Conclusion  ...............................................................................18  
3. OBJECTIVES AND ENDPOINTS  ............................................................................19  
3.1. Objectives  ...................................................................................................................19  
3.1.1.  Primary Objective  .......................................................................................................19  
3.1.2.  Exploratory Objectives  ...............................................................................................19  
3.2. Estimands ....................................................................................................................19  
3.3. Endpoints ....................................................................................................................19  
3.3.1.  Primary Endpoints (Safety) ........................................................................................19  
3.3.2.  Exploratory Endpoints  ................................................................................................19  
4. STUDY DESIGN  .......................................................................................................20  
4.1. Overall Design  ............................................................................................................20  
Protocol C3300-102 
3 4.1.1.  Study Periods ..............................................................................................................20  
4.1.1.1.  Screening Period .........................................................................................................20  
4.1.1.2.  Clinic Period  ...............................................................................................................21  
4.1.1.3.  Follow-up Period ........................................................................................................21  
4.2. Scientific Rationale for Study Design ........................................................................21  
4.2.1.  Subject Input into Design  ...........................................................................................22  
4.3. Justification for Dose  ..................................................................................................22  
4.4. End of Study Definition ..............................................................................................22  
5. STUDY POPULATION  .............................................................................................23  
5.1. Inclusion Criteria  ........................................................................................................23  
Age ..............................................................................................................................23  
Type of Subj ect and Disease Characteristics  ..............................................................23  
Weight .........................................................................................................................23  
Sex ..............................................................................................................................23  
Informed Consent .......................................................................................................24  
5.2. Exclusion Criteria  .......................................................................................................24  
Medical Conditions .....................................................................................................24  
Prior/Concomita nt Therapy  ........................................................................................24  
Prior/Concurren t Clinical Study Experience  ..............................................................25  
Diagnostic Assessm ents ..............................................................................................25  
Other Exclusions .........................................................................................................25  
5.3. Lifestyle Considerations  .............................................................................................26  
5.3.1.  Meals and Dietary Restrictions  ...................................................................................26  
5.3.2.  Caffeine, Alcohol, and Tobacco .................................................................................26  
5.3.3.  Activity  .......................................................................................................................26  
5.4. Screen Failures  ............................................................................................................26  
6. STUDY INTERVENTION  ........................................................................................27  
6.1. Study Interventions Administered  ..............................................................................28  
6.1.1.  Dosing Instructions .....................................................................................................28  
6.2. Preparation/Handling/Storage/Accountability  ............................................................28  
6.3. Measures to Minimize Bias: Randomization and Blinding  ........................................29  
6.3.1.  Randomization ............................................................................................................29  
6.3.2.  Blinding ......................................................................................................................29  
Protocol C3300-102 
4 6.4. Study Intervention Compliance ..................................................................................30  
6.5. Concomitant Therapy .................................................................................................30  
6.5.1.  Rescue Medicine  .........................................................................................................31  
6.6. Dose Modification  ......................................................................................................31  
6.7. Intervention After the End of the Study  .....................................................................31  
7. DISCONTINUATION OF STUDY INTERVENTION AND SUBJECT
DISCONTINUATION/
WITHDRAWAL  ..................................................................32  
7.1. Discontinuation of Study Inte rvention  ........................................................................32  
7.1.1.  Study Suspension or Termination ...............................................................................32  
7.2. Subject Discontinuation/Withdrawal from the Study  .................................................33  
7.3. Lost to Follow-up .......................................................................................................33  
8. STUDY ASSESSMENTS AND PROCEDURES  ......................................................34  
8.1. Efficacy Assessments  .................................................................................................34  
8.2. Safety Assessments  .....................................................................................................34  
8.2.1.  Physical Examinations  ................................................................................................34  
8.2.2.  Vital Signs  ..................................................................................................................35  
8.2.3.  Electrocardiograms  .....................................................................................................35  
8.2.4.  Clinical Safety Laboratory Assessments  ....................................................................35  
8.2.5.  Bladd er and Bowel Movement Diary  .........................................................................36  
8.3. Adverse Events and Serious Adverse Events .............................................................36  
8.3.1.  Time Period and Frequency for Collecting AE and SAE Information .......................37  
8.3.2.  Method of Detecting AEs and SAEs ..........................................................................37  
8.3.3.  Follow-up o f AEs and SAEs  .......................................................................................37  
8.3.4.  Regulatory Reporting Requirements for SAEs ...........................................................38  
8.3.5.  Pregnancy ...................................................................................................................38  
8.3.6.  Cardiovascular and Death Events ...............................................................................38  
8.3.7.  Disease- related Events and/or Disease -related Outcomes Not Qualifying as 
AEs or SAEs  ...............................................................................................................38  
8.3.8.  Adverse Events of Special Interest  .............................................................................38  
8.4. Treatment of Overdose  ...............................................................................................39  
8.5. Pharmacokinetics  ........................................................................................................39  
8.6. Microbiome  .................................................................................................................39  
8.7. Pharmacodynamics .....................................................................................................40  
Protocol  C3300-102 
 5  
    8.8. Genetics  ......................................................................................................................40  
8.9. Biomarkers  ..................................................................................................................40  
8.10.  Immunogenicity Assessments  ....................................................................................40  
8.11.  Medical Resource U tilization and Health Economics  ................................................40  
9. STATISTICAL CONSIDERATIONS .......................................................................41  
9.1. Statistical Hypotheses  .................................................................................................41  
9.2. Sample Size Determination  ........................................................................................41  
9.3. Populations for Analyses ............................................................................................41  
9.4. Statistical Analyses  .....................................................................................................41  
9.4.1.  General Considerations  ...............................................................................................41  
9.4.2.  Primary Endpoints Analyses .......................................................................................42  
9.4.3.  Secondary Endpoint Analysis .....................................................................................42  
9.4.4.  Exploratory Endpoints Analyses  ................................................................................42  
9.4.5.  Safety Analyses  ..........................................................................................................42  
9.4.6.  Other Analysis/Analyses  ............................................................................................43  
9.5. Interim Analyses  .........................................................................................................43  
9.6. Data Monitoring Committee (DMC) ..........................................................................43  
10. SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS  ..................................................................................................44  
10.1.  Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ....................44  
10.1.1.  Regulatory and Ethical Considerations  ......................................................................44  
10.1.2.  Financial Disclosure  ...................................................................................................44  
10.1.3.  Informed Consent Process ..........................................................................................44  
10.1.4.  Data Protection  ...........................................................................................................45  
10.1.5.  Committee Structure  ...................................................................................................45  
10.1.6.  Dissemination of Clinical Study Data  ........................................................................45  
10.1.7.  Data Quality Assurance  ..............................................................................................46  
10.1.8.  Source Documents ......................................................................................................46  
10.1.9.  Study and Site Start and Closure  ................................................................................47  
10.1.10.  Publication Policy  .......................................................................................................47  
10.2.  Appendix 2: Clinical Laboratory Tests  .......................................................................48  
10.3.  Appendix 3: Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow -up, and Reporting ........................................................................50
 
Protocol  C3300-102 
 6  
    10.3.1.  Definition of AE and TEAE .......................................................................................50  
10.3.1.1.  AE Definition  ..............................................................................................................50  
10.3.1.2.  TEAE Definition  .........................................................................................................50  
10.3.1.3.  Events Meeting the AE Definition .............................................................................50  
10.3.1.4.  Events NOT  Meeting the AE Definition  ....................................................................51  
10.3.2.  Definition of SAE  .......................................................................................................51  
10.3.3.  Recording and Follow- up of AE and/or SAE .............................................................52  
10.3.3.1.  AE and SAE Recording ..............................................................................................52  
10.3.3.2.  Assessment of Intensity/Severity  ................................................................................53  
10.3.3.3.  Assessment of Causality  .............................................................................................53  
10.3.3.4.  Follow-up of AEs and SAEs .......................................................................................54  
10.3.4.  Reporting of SAEs ......................................................................................................54  
10.3.4.1.  SAE Reporting to Ironwood Global Patie nt Safety via an Electronic Data 
Collection Tool ...........................................................................................................54  
10.3.4.2.  SAE Reporting to Ironwood Global Patient Safety via Paper SAE Report 
Form  ............................................................................................................................55  
10.4.  Appendix 4: Contraceptive Guidance and Collection of Pregnancy Information  .................................................................................................................56
 
10.4.1.  Definitions  ..................................................................................................................56  
10.4.1.1.  Women of Childbearing Potential (WOCBP) ............................................................56  
10.4.1.2.  Women Not Considered Women of Childbearing Potential  ......................................56  
10.4.2.  Contraception Guidance .............................................................................................56  
10.4.2.1.  Collection of Pregnancy Information  .........................................................................57  
10.5.  Appendix 5: Abbreviations .........................................................................................58  
10.6.  Appendix 6: Protocol Signatures ................................................................................61  
10.6.1.  Sponsor Signature .......................................................................................................61  
10.6.2.  Investigator Signature  .................................................................................................62  
11. REFERENCES ...........................................................................................................63  
Protocol  C3300-102 
 7  
    LIST OF TABLES  
Table  1: Schedule of Activities  .................................................................................................11  
Table  2: Protocol- required Safety Laboratory Assessments  .....................................................49  
Table  3: List of Abbreviations ..................................................................................................58  
 
LIST OF FIGURES  
Figure 1:  Schematic of Study Design  .........................................................................................10  
 
Protocol  C3300-102 
 8  
    1. PROTOCOL SUMMARY  
1.1. Synopsis  
Protocol Title  
A Phase 1 Placebo -controlled Study of the Safety and Tolerability of Rectally Administered, 
Multiple -ascending Doses of IW-3300 in Healthy Subjects 
Short Title  
A Phase 1 Study of Multiple- ascending Doses of IW-3300 in Healthy Subjects 
Rationale 
The aim  of this study is to assess the effects of IW ‑3300 administered rectally , once- daily  for 
7 days in healthy subjects. IW ‑3300 is a novel, 13- amino -acid, guanylate cyclase C (GC -C) 
agonist peptide. GC- C, the target of IW ‑3300, is predominantly expressed on t he luminal surface 
of the small and large intestines. Preclinical models provide preliminary evidence which suggests 
that when GC- C receptors are stimulated, intracellular cyclic guanosine monophosphate (cGMP) 
is secreted across the basolateral membrane of  colonic epithelial cells in the submucosa by 
multidrug resistance proteins MRP 4 and MRP5. This decreases the activity of afferent nerve 
fibers located in the colonic wall, resulting in reduced visceral pain, which ultimately produces an analgesic effect i n other organs of the abdominopelvic region via action mediated through the 
common afferent pathways.( 1, 2) Because of these  analgesic effects, IW‑ 3300 is being 
developed as a rectally -administered therapeutic for the treatment of interstitial cystitis/bladder 
pain syndrome (IC/BPS), a chronic and debilitating condition for whic h there are no  safe, 
effective treatment options. Data from th is current study will be used to enable a Phase  2 safety, 
tolerability, and efficacy study of IW‑ 3300 in subjects with IC/BPS. More information on the 
pharmacology and safety  of IW‑ 3300 is provided in Section 2. 
Objectives and Endpoints  
Objective  Endpoints  
Primary  
To assess the safety and tolerability of 7 -day 
dosing with multiple -ascending doses of IW ‑3300  
administered rectally via enema in healthy 
subjects  Incidence of treatment-emergent adverse events (TEAEs)  
Incidence of treatment-emergent serious adverse events (TESAEs)  
Exploratory 
To summarize the pharmacokinetics (PK ) of 
7‑day dosing with IW‑3300 administered rectally 
via enema in healthy subjects  PK parameters ( IW‑3300 and metabolites in 
plasma)  
To explore potential changes to the microbiome 
with 7 ‑day dosing with IW‑ 3300  administered 
rectally via enema in healthy subjects Change in 16s  RNA based analysis of gut 
microbiome composition at the genus level from baseline to 7 days post IW‑ 3300 administration 
Protocol  C3300-102 
 9  
    Overall Design  
This is a Phase 1, single-center, randomized, double-blind, placebo- controlled, multiple -
ascending -dose study of IW‑3300 administered rectally as a low -volume enema in healthy adult 
subjects. This study will assess the effect of IW‑ 3300 on saf ety, tolerability , and PK, and also 
explore the potential  effect of IW‑3300 on gut microbiome composition . 
Subjects in e ach cohort will progress through 3 study periods: (1) Screening Period, (2)  Clinic 
Period, and (3)  Follow-up Period; these periods and the progression between cohorts are 
illustrated in the study schematic (Figure  1). 
A Dose Escalation Committee will conduct blinded reviews of all the safety/tolerability 
parameters of the IW‑3300 100‑μ g dosing cohort through Discharge (Day 8) in order to make a 
decision regarding dose escalation to the next IW‑3300 dosing cohort. The Dose Escalation 
Committee will include sponsor and contract research organization (CRO) representatives.  
Disclosure Stat ement  
This is a multiple -ascending -dose safety and tolerability study with 4 possible treatments 
(placebo, 2 dose levels of IW ‑3300, and an optional 3rd dose level of IW‑ 3300) that is subject ‑ 
and investigator ‑blinded.  
Number of Subjects  
A total of up to 2 7 subjects will be randomized in the study (2  cohorts of 9 subjects each, and an 
optional 3rd cohort of 9 additional subjects). Within each cohort, 6 subjects will be randomized 
to IW ‑3300 and 3 subjects will be randomized to placebo.  
Intervention Groups a nd Duration 
The study will evaluate multiple -ascending doses of IW ‑3300 in a double-blind manner. The 
9 subjects within each cohort will be randomized to receive IW‑3300 (6  subjects) or placebo 
(3 subjects), administered rectally (as a low -volume [20 mL] e nema) following a fast of at least 
6 hours (refer to th e Schedule of Activities [SoA ; Table  1] for additional details regarding dosing 
instructions) once daily for 7 days. The planned cohorts are: 
• Cohort 1: IW ‑3300 100 μg or matching placebo rectal dose once daily  
• Cohort 2: IW ‑3300 300 μg or matching placebo rectal dose once daily  
• Cohort 3 (optional): IW ‑3300 >100 μg but <300 μg or matchi ng placebo rectal dose 
once daily (decision to enroll this cohort will be determined after safety reviews of 
previous cohorts, in the case of intolerability at 300 μg but tolerability at 100 μg)  
Dosing in Cohort 2 and optional Cohort 3 will only proceed following a review of safety data 
from the previous cohort(s) , including adverse events (AEs), clinical laboratory test results, vital 
signs, and 12-lead ECGs. The determination of dose escalation will be made at a meeting of the 
Dose Escalation Committee.  
Treatment duration will be 7 days; subjects will be followed in the Phase  1 clinical research unit 
(CRU) for the duration of dosing, until at least 24 hours after the last dose of study drug and 
Protocol  C3300-102 
 10  
    contacted by phone for follow-up approximately 2 week s after the last dose. Total subject 
participation will be 29 to 57 days , including the Screening, Clinic, and Follow -up Periods. 
Data Monitoring Committee: No  
The study will utilize a Dose Escalation Committee to review safety data for Cohort 1 in order to 
make de cisions about dose escalation to Cohort 2. An optional cohort, Cohort 3, may be enrolled 
based on a review of safety data from Cohorts 1 and 2. 
1.2. Schema  
Figure 1: Schematic of Study Design  
Dose
EscalationScreening
Visit
(Day -36
to Day -8)Check -in
(Day -1)Discharge
(Day 8)Follow -up
Phone Call
(Day 21 +3)Dosing
(Day 1)7 to 35 days 9 days 13 daysScreening Period Clinic Period Follow -up Period
Dose Escalation
Review
Cohort 2Cohort 1
Protocol  C3300-102 
 11  
    1.3. Schedule of Activities  
Table  1: Schedule of Activities  
Study Period→  Screening  
Period  Clinic Period Follow -up 
Period  
Study  
Procedure↓  Visit/Day→  Screening 
Visit  
Day ‑36 to 
Day ‑8 Check -in 
Day ‑1 Dosing  
Day 1 Days  2 
through 6  Day 7 Discharge  
Day 8a/ 
ET Follow -up 
Phone Call 
Day 21 
(+3 days)  
Informed consent  X       
Eligibility criteria X X      
Medical history  X       
Demographics  X       
Body weight & heightb X  Pre   X  
Urine drug & alcohol screen  X X      
Physical examinationc X X Pre Pre Pre X  
Rectal examinationd X X Pre Pre Pre X  
Vital signse X X Post: 0.5, 2, 4, 
and 8h (±10m)  Days 3 
through 6  
Pre: 0  (≤25m)  Post: 0.5, 2, 4, 
and 8h (±10m)    
Orthostatic blood pressure and 
pulsef   Pre: 0  (≤25m)  
Post: 1 and 6h 
(±20m) Day 2 only 
Pre: 0  (≤25m)  Pre: 0  (≤25m)  
Post: 1 and 6h 
(±20m) 24h post -
Day 7 dose 
(±20m)  
Triplicate 12 -lead ECGg X X Pre: 1h (±30m)  
Post: 2h (±30m)  Pre: 1h 
(±30m)  
Post: 2h 
(±30m)  Pre: 1h 
(±30m)  
Post: 2h 
(±30m)    
Protocol  C3300-102 
 12  
    Study Period→  Screening  
Period  Clinic Period Follow -up 
Period  
Study  
Procedure↓  Visit/Day→  Screening 
Visit  
Day ‑36 to 
Day ‑8 Check -in 
Day ‑1 Dosing  
Day 1 Days  2 
through 6  Day 7 Discharge  
Day 8a/ 
ET Follow -up 
Phone Call 
Day 21 
(+3 days)  
Clinical chemistry, hematology, 
urinalysis  X X Pre: 0  (≤15m, 
≤30m for UA)  
Post: 6h (±30m)  Day 4 only 
Pre: 0  (≤15m, 
≤30m for UA)   X  
ESR and CRP blood drawh  X    X  
FSH X       
HCGi X X      
SARS‑CoV‑2 testing  X X      
HIV & hepatitis panel  X       
BBMD training  X       
BBMD dispensed  X X      
Daily BBMD completionj Day ‑8 through 
Day ‑2 X X X X X  
BBMD collection and reviewk  X    X  
Concomitant medications X X X X X X X 
AE monitoring  X X X X X X X 
Subject confinement to clinicl  X X X X X  
Start of predose fastm   Pre: ≥6h  Pre: ≥6h  Pre: ≥6h    
Randomization    X     
Protocol  C3300-102 
 14  
    f For orthostatic blood pressure and pulse measurements, the subject must lie quietly for ≥ 5 minutes before supine/semisu pine blood pressure and pulse 
measurements are taken, then assume standing position for 3 minutes before standing blood pressure and pulse measurements are taken. If a subject has 
orthostatic symptoms upon standing (eg, palpitation, dizziness), they will b e assisted and asked to lie down without waiting the 3 minutes for vital sign 
assessment. Orthostatic measurements may be taken at other vital signs collection timepoints if clinically indicated, at the discretion of the investigator. When 
applicable, vita l sign measurements will be obtained before blood draws.  
g ECGs should be obtained after the subject has been supine for at least 5 minutes. At each timepoint required, 3 individual ECG tracings should be obtained as 
closely as possible in succession, but no more than 2  minutes apart. The full set of triplicates should be completed in less than 4 minutes.  
h Elevated inflammatory markers (ESR, CRP), and/or relevant symptoms (eg, rectal pain, hematochezia) may be suggestive of colonic inflammation; subjects 
with these signs or symptoms should undergo recto- sigmoidoscopy. If this is negative, a colonoscopy may be performed after a discussion  between the 
investigator and the Sponsor.  
i HCG at Screening will be a blood -based test. HCG at Check -in/Day  ‑1 will be a urine -based test.  
j The BM portion of the BBMD will be completed by the subject on an event -driven basis. For subjects with Screening Visits earlier than Day  ‑9, CRU staff will 
call subjects on Day ‑9 to remind them to begin recording their BMs in the BBMD the follow ing day, answer any questions, and provide additional BM pages 
via email, if needed. Bladder information in the BBMD will be collected predose on each dosing day, with a 24‑ hour recall period at each timepoint.  
k CRU staff will review the subject’s Screening Period BBMD at Check -in to confirm that subjects have at least 3  bowel movements during the 7  days prior to 
Check -in (Days  ‑8 through ‑2) and no more than 3 bowel movements per day to be eligible for the study; CRU staff will collect the subject’s Clinic Period 
BBMD at Discharge.  
l Subjects will remain at the CRU from Check -in (Day  ‑1) through Discharge (Day  8). 
m Subjects will fast for at least 6  hours prior to dosing on Days  1 through 7 and for at least 1 hour following dosing. During these times, water is permitted.  
n Study drug ( IW‑3300  or placebo low- volume enema) will be administered rectally once daily, after a fast of at least 6  hours; water is permitted. Subjects will 
be encouraged to empty their bowels in the morning prior to dosing, if possible. Subjects will be instructed to lie on their left side with their left leg extend ed 
and their right leg slightly bent. Study drug will be dispensed in capped syringes with a separately packaged colon tip appli cator. The CRU dosing staff will 
remove the cap from the syringe, attach the colon tip applicator, prime the syringe and applicator to 20 mL, and slowly administer  by inserting the contents of 
the syringe into the rectum . After the full dose has been administ ered, subjects will lie on their left side for at least 30  minutes to allow the liquid to distribute 
throughout their intestines, followed by at least 30  additional minutes in the semisupine position. CRU staff will monitor subjects for leakage of the stud y drug 
from the rectum during the initial 3 0 minutes post administration. Subjects should avoid using the bathroom and hold in the enema for as long as possible (at 
least 1  hour).  
o PK blood draw s at 0.5- and 1 -hour postdose should be collected while the subject maintains the position noted in the dosing instructions above.  
p At Check -in/Day ‑1, the subject will bring in a stool sample using the sample collection kit issued by the site. Between Day 7 (postdose) and Day  8 
(predischarge), the first stool passed will be collected. If no stool is passed during this time, the subject will be discharged with a stool collection kit and asked 
to return the sample to the CRU.  
q The predose hemoccult testing may be performed using a stool sample obtained any time from Check- in (Day ‑1) to predose. If the subject does not produce a 
stool sample, stool that is present on the Day 1 (predose) digital rectal examination may be used. The Discharge ( Day 8) hemoccult testing may be performed 
using a stool sample obtained any time from postdose on Day 7 to Discharge ( Day 8). If the subject does not produce a stool sample, stool that is present on the 
Discharge ( Day 8) digital rectal examination may be used.  
r CRU staff will contact subjects by phone for safety follow -up (at the discretion o f the investigator, subjects may be requested to return to the CRU for their 
follow -up contact).  
Protocol  C3300-102 
 15  
    2. INTRODUCTION  
IW‑3300 is being developed for the treatment of bladder pain associated with interstitial 
cystitis/bladder pain syndrome (IC/BPS ). 
2.1. Study Rationale  
This clinical study is the second  clinical study designed as a multip le-ascending- dose, safety , and 
tolerability stud y with IW ‑3300. IW ‑3300 will be administered rectally as a low -volume (2 0 mL) 
enema; this route of administration was selected to target the effects of IW‑ 3300 to the afferent 
nerve fibers in the colonic wall to reduce visceral pain in the pelvic region wh ile minimizing the 
risk of diarrhea . Dosing for rectal administration will be initiated at 100 μ g and will not go 
higher than 300 μ g, which is approximately 80- fold lower than the human-equivalent dose 
[HED] based on body weight conversion of the lowest no adverse effect level ( NOAEL ) 
(24,000 μ g) identified in nonclinical toxicology studies.  
2.2. Background 
IW‑3300 is being developed for the treatment of bladder pain associated with IC/BPS. IW ‑3300 
is a novel, 13- amino -acid, guanylate cyclase C (GC-C) agonist peptide. GC- C, the target of 
IW‑3300, is predominantly expressed on the luminal surface of the small and large intestines. 
Preclinical models provide preliminary evidence which suggests that w hen GC -C receptors are 
stimulated, intracellular cyclic guanosine monophosphate (cGMP) is secreted across the 
basolateral membrane of colonic epithelial cells in the submucosa by multidrug resistance proteins MRP4 and MRP5. This decreases the activity of afferent nerve fibers located in the 
colonic wall, resulting in reduced visceral pain, which ultimately produces an analgesic effect in 
other organs of the abdominopelvic region via action mediated through the common afferent pathways.( 1, 2) 
Experiments conducted in animals indicate that colonic hypersensitivity induces persistent hypersensitivity of bladder afferent pathways in the absence of bladder pathology.( 2) 
Hypersensitivity of bladder afferent pathways resembles the symptoms observed in patients with 
IC/BPS. Afferent neurons are known to have peripheral endings in both the colon and the 
bladder, and the axons of colonic and bladder neurons travel through the same splanchnic and pelvic nerves. These nonclinical observations support the concept of cross -organ sensitization 
and suggest that GC- C agonists such as IW ‑3300 may be useful clinically for the treatment of 
bladder pain associated with IC/BPS.  
IW‑3300 has shown beneficial effects in reducing visceral pain in several animal models, 
including models of colonic pain and models of extra- intestinal chronic pelvic pain following 
intracolonic or intrarectal administration. IW ‑3300 (3  μg/kg/day), administered either 
intracolonically or orally to female rats, reduced endometriosis -induced mechanical hind paw 
allodynia. When administered intracolonically (1, 3, or 10 μg/kg/day), IW‑3300 reduced 
endometriosis-induced vulvar pain in a dose-dependent manner. In a rat model of chronic radiation proctopathy induced either by fractionated dose (total dose 48 Gray) or single high dose 
(25 Gray) of radiation, IW‑3300 (3  μg/kg/day) administered intracolonically reversed colorectal 
and bladder hypersensitivity. IW ‑3300 (3  μg/kg/day) administered intrarectally reduced vaginal 
Protocol  C3300-102 
 17  
    2.3. Benefit/Risk Assessment  
Available data with IW ‑3300 support a favorable risk -benefit profile. When administered orally, 
GC-C agonists may cause diarrhea and dehydration. This should be minimized in this study as 
IW‑3300 is being administered intrarectally as a low -volume enema. More detailed information 
about the known and expected benefits and potential risks of IW ‑3300 may be found in the IB . 
2.3.1. Risk Assessment  
Potential Risk of 
Clinical Significance  Summary of Data/Rationale for Risk  Mitigation Strategy 
Study Intervention: IW‑3300  
Potential for diarrhea  
and secondary  
dehydration  These are class effects of  
GC‑C agonis m or effects 
observed  in nonclinical 
safety pharmacology and toxicology studies of IW‑3300.  Intrarectal administration will likely decrease the 
risk of diarrhea and subsequent dehydration. The 
study design includes dose escalation to closely 
monitor subject safety  and tolerability at each 
dose level before dosing with a higher dose ; a 
Dose Escalation Committee will conduct blinded reviews of all the safety parameters of the dosing cohort through Discharge ( Day 8) in order to 
make decisions regarding escalation to the next dose. Orthostatic vital sign measurements will be 
taken to evaluate the potential for volume 
depletion. The daily  bowel movement ( BM) 
frequency and stool consistency will be monitored 
in real time  to evaluate changes in bowel habits 
and the potential risk of diarrhea. Stopping rules will also be  in place to evaluate continued dosing 
(Section  7.1.1 ); dosing within a cohort may be 
temporarily suspended in the event of a diarrhea or dehydration serious adverse event (SAE); ≥1 subject with Grade 3 diarrhea (increase from 
baseline of >7 stools per day  and/or watery stools 
[Bristol Stool Form Scale  {BSFS} score of 7] 
resulting in a  limiting of  self-care activities) or 
dehydration (hospitalization indicated); or ≥3 subjects with Grade 2 diarrhea (increase from 
baseline of 4 to 6 stools per day  and/or watery 
stools [BSFS score of 7] resulting in a limiting of 
instrumental activities) or dehydration (intravenous fluids indicated) . 
Protocol  C3300-102 
 18  
    Potential Risk of 
Clinical Significance  Summary of Data/Rationale for Risk  Mitigation Strategy 
Unknown AEs, 
laboratory abnormalities, or other safety findings with a novel study drug This is a n early phase 
study with IW ‑3300 and, 
as such, limited clinical 
data are available.  The study design includes dose escalation to closely monitor subject safety  at each dose level 
before dosing with a higher dose ; a Dose 
Escalation Committee will conduct blinded reviews of all the safety parameters of the dosing cohort through Discharge ( Day 8) in order to 
make decisions regarding escalation to the next dose. Stopping rules are also in place  to evaluate 
continued dosing within a cohort (Section 7.1.1 ); 
dosing within a cohort may be temporarily suspended in the event of an SAE considered 
related to study drug; ≥1  subject with a Grade 3 
(severe or medically significant) or higher AE 
considered related to study drug; or ≥ 3 subjects 
with Grade 2 (moderate) or higher AEs 
considered related to study drug. 
Study drug will be administered rectally. Rectally administered medications may 
potentially be associated 
with AEs such as local 
trauma/discomfort , 
irritation, or bleeding.  The study excludes subjects for whom rectal 
administration would be anticipated to be a safety concern . The low -volume (20 ml) enema used in 
this study is expected to be a lower risk than  
higher volume  enemas.  Nonclinical toxicology 
studies of IW ‑3300 have shown no signs of local 
trauma following intrarectal administration. Study  C330 0‑101, a  single -ascending dose 
clinical study testing IW‑3300 doses up to 
2500  μg in healthy subjects is currently ongoing.  
Study Procedures  
Venipuncture will be performed during the study.  There is the risk of bleeding, bruising, hematoma formation, and 
infection at the 
venipuncture site.  Only appropriately qualified personnel will 
perform the blood draw.  Subjects will be 
monitored for these risks and managed 
appropriately.  
2.3.2. Benefit Assessment  
Benefits to individual subjects may include access to m edical evaluations/assessments associated 
with study procedures (eg, physical examinations, ECGs, laboratory evaluations , SARS‑CoV‑2 
[severe acute respiratory syndrome coronavirus 2 ; COVID‑ 19] diagnostic testing). 
2.3.3. Overall Benefit: Risk Conclusion  
Taking into account the measures taken to minimize risk to subjects participating in this study, 
the potential  risks identified in association with IW ‑3300 are justified by the anticipated benefits 
to patients with IC/BPS . 
Protocol  C3300-102 
 19  
    3. OBJECTIVES  AND ENDPOINTS  
3.1. Objectives  
3.1.1. Primary Objective  
To assess the safety and tolerability of 7 -day dosing with multiple-ascending doses of IW‑3300 
administered rectally via enema in healthy subjects 
3.1.2. Exploratory Objectives 
The exploratory objectives are: 
• To summarize the PK of 7‑ day dosing with IW ‑3300 administered rectally via enema 
in healthy subjects  
• To explore potential changes to the micr obiome with 7‑ day dosing with IW ‑3300 
administered rectally via enema in healthy subjects 
3.2. Estimands  
Not applicable for this Phase 1 study  
3.3. Endpoints 
3.3.1. Primary Endpoints (Safety)  
The primary endpoints are: 
• Incidence of TEAEs  
• Incidence of TESAEs  
3.3.2. Exploratory Endpoints 
The exploratory endpoints are: 
• PK parameters ( IW‑3300 and metabolites in plasma)  
• Change in 16s RNA based analysis of gut microbiome composition at the genus level 
from baseline to 7 days post IW‑ 3300 administration  
Protocol  C3300-102 
 20  
    4. STUDY DESIGN  
4.1. Overal l Design  
This is a Phase 1, single-center, randomized, double-blind, placebo- controlled, multiple -
ascending -dose study of IW‑3300 administered rectally , once- daily , for 7 days as a low -volume 
enema in healthy adult subjects . This study will assess the effect of IW‑3300 on safety, 
tolerability, and PK, and also explore the potential effect of IW‑ 3300 on gut microbiome 
composition. 
Subjects in e ach dosing cohort will progress through 3 study periods: (1) Screening Period, 
(2) Clinic Period, and (3)  Follow-up Period; these periods and the progression between cohorts 
are illustrated in the study schematic (Figure 1 ). Treatment duration will be 7 days; subjects will 
be followed in the Phase  1 clinical research unit (CRU) for the duration of dosing, until at least 
24 hours after the last dose of study drug and contacted by phone for follow-up approximately 
14 days after the last dose. Total subject participation will be 29 to 57 days , including the 
Screening, Clinic, and Follow -up Periods. 
The study will evaluate multiple -ascending doses of IW ‑3300 in a double -blind manner. The 
9 subjects within each cohort will be randomized to receive IW‑3300 (6  subjects) or placebo 
(3 subjects), administered rectally , once- daily  for 7 days (as a low -volume [20 mL] enema) 
following a fast of at least 6  hours (refer to the SoA [ Table  1] for additional details regarding 
dosing instructions). The planned cohorts are: 
• Cohort 1: IW ‑3300 100 μg or matching placebo rectal dose once daily  
• Cohort 2: IW ‑3300 300 μg or matching placebo rectal dose once daily  
• Cohort 3 (optional): IW ‑3300 >100 μg but <300 μg or matching placebo rectal dose 
once daily (decision to enroll this cohort will be determined after safety reviews of 
previous cohorts, in the case of intolerability at 300 μg but tolerability at 100 μg)  
A Dose Escalation Committee will conduct blinded reviews of all the safety/tolerability 
parameters of the IW‑3300 100- μg dosing cohort through Discharge (Day 8) in order to ma ke a 
decision regarding dose escalation to the next IW‑3300 dosing cohort. The Dose Escalation 
Committee will include sponsor and contract research organization (CRO) representatives.  Dose 
escalation is detailed in Section  6.6. 
4.1.1. Study Periods  
4.1.1.1. Screening Period  
The Screening Period will begin with the signature of the informed consent form (ICF ) at the 
Screening  Visit (which can occur from Day ‑36 to Day  ‑8) and will last 7 to 35 days. At the 
Screening  Visit, subjects will undergo preliminary screening procedures to ensure that they meet 
the inclusion and exclusion criteria for the study. Eligible subjects will re ceive the BM portion of 
the bladder and bowel movement diary (B BMD), a paper-based diary to complete on an event-
driven basis (ie, for each  BM) at home, and training on how to complete it to record their bowel 
habits. Subjects will complete the BM portion of the B BMD daily only for the 7 days before 
Protocol  C3300-102 
 21  
    Check -in on Day  ‑1. The end of the Screening Period will coincide with the beginning of the 
Clinic Period at Check -in (Day ‑1). 
4.1.1.2. Clinic Period  
The Clinic Period will begin at Check -in to the Phase 1 CRU on Day  ‑1 (the day before dosing), 
and will end at the time of Discharge on Day  8 (the day after dosing). Following confirmation of 
eligibility at Check -in, subjects will be admitted to the CRU an d will undergo baseline 
procedures. On the morning of Day  1 (note that there is no Day 0), subjects in each cohort will 
undergo predose assessments and will be randomized in a 2:1 ratio to receive IW ‑3300 or 
matching placebo after a fast of at least 6 hours. 
The assessments conduc ted during the Clinic Period are shown in the SOA ( Table  1). Daily 
safety assessments will be performed . Subjects will continue  to enter their BM information into 
the BBMD on an event-driven basis. The questions related to  bladder/ urinary  symptoms  in the 
BBMD will be collected predose on each dosing day, with a 24-hour recall period at each 
timepoint to ascertain any undesirable effects on the bladder or potential urinary symptoms . 
Blood samples for PK assessments will be collected at specified times predose (blood) and 
postdose (blood and stool). Subjects will be confined to the CRU from Check -in (Day ‑1) 
through Discharge ( Day 8), which will occur after completion of the assessments (at least 
24 hours after the last administration of study drug) and at the investigator’s discretion.  
4.1.1.3. Follow- up Period  
The Follow- up Period will start immediately after s ubjects are discharged from the Phase  1 CRU 
on Day  8 and will last until Day  21 (+3). On Day  21 (+3), the Phase 1 CRU will contact subjects 
for the Follow -up Phone Call (at the discretion of the investigator, subjects may be requested to 
return to the Phase 1 CRU for their follow -up contact). The Follow-up Phone Call will be 
considered the end of the study for that subject. 
4.2. Scientific Rationale for Study Design 
A randomized, double-blind, placebo-controlled study design was chosen to investigate the 
effects of IW ‑3300 administered  once daily for 7 days as a low -volume enema . Subjects will be 
randomized within each cohort to ensure that the treatment groups are comparable and  to 
minimize the potential for selection bias. The study will be double -blind to ensure that the 
subjects and CRU staff are unaware of the treatment assignment and to minimize the potential for bias in study assessments or AE reporting. Placebo was chosen as the control so that the rate 
of spontaneously occurring AEs can be determined and to reduce the potential for bias in the 
reporting of AEs. 
To ensure a thorough assessment of safety, s ubjects will be confined to the CRU for the duration 
of the Clinic Period, from Check -in (Day ‑1) through until Discharge ( Day 8), which will occur 
after completion of the assessments (at least 2 4 hours after administration of study drug) and at 
the investigator’s discretion.  CRU staff will contact subjects for the Follow -up Phone Call on 
Day 21 (+3), conducted 14 days after the last dose, for safety follow -up; at the discretion of the 
investigator, subjects may be requested to return to the CRU for their follow -up contact. 
To evaluate any effects of IW‑ 3300 on bowel and bladder function, subjects will complete the 
BM portion of the BBMD on 7 consecutive days during the Screening Period to establish a 
Protocol  C3300-102 
 23  
    5. STUDY POPULATION  
Prospective approval of protocol deviations to recruitment an d enrollment criteria, also known as 
protocol waivers or exemptions, is not permitted. 
5.1. Inclusion Criteria  
Subject s are eligible to be included in the study only if all of the following criteria apply:  
Age 
1. Subject is 18 to 60 years of age, inclusive, at the time of signing the ICF. 
Type of Subject  and Disease Characteristics  
2. Subject is medically healthy with no clinically significant findings during medical 
evaluation including physical examination, 12-lead ECG, and c linical laboratory tests 
(serum chemistry, hematology, urinalysis, and urine drug and alcohol screen). (NOTE: In making this determination, the investigator or designee will consider whether any finding could prevent the subject from performing any of the protocol -specified assessments, 
could represent a condition that would exclude the subject from the study, could represent a safety concern if the subject participates in the study, or could confound the study-specified assessments [eg, incontinence, overa ctive bladder, prostatitis, urinary tract 
infection]).  
3. Subject has normal formed bowel movements (≥3 per week and ≤3 per day; average BSFS score of >2  and <6, as reported in the BBMD during the 7 days before Check- in 
[Day  ‑1]). 
4. Subject agrees to refrain from making any new or major lifestyle changes (eg, new diet or exercise regimen) from the Screening Visit until after the Follow -up Phone Call on 
Day 21. 
5. If subject is ≥4 5 years of age, subject is compliant with colorectal cancer screening 
guidelines according to the American College of Gastroenterology (ACG) Clinical 
Guidelines: Colorectal Cancer Screening 2021. ( 8) 
Weight 
6. Subject’s body mass index (BMI) is within the range 18.5 to 35.0 kg/m2 (inclusive) at the 
Screening Visit.  
Sex 
7. Male and female subjects 
a. Female subject is of nonchildbearing potential (ie, women who are postmenopausal 
[greater than 12  months without menses] or who have had a procedure such as a 
bilateral oophorectomy, bilateral salpingectomy, or hysterectomy).  
b. Subject is willing to abstain from sexual intercourse during the period of confinement 
in the CRU.  
Protocol  C3300-102 
 24  
    c. Male subject and female partner (s) are willing to use a double- barrier method of 
contraception during the study (eg, diaphragm with spermicide plus a condom, 
condom with spermicide plus a diaphragm or cer vical cap), from the Screening Visit 
until after the Follow -up Phone Call on Day 21. 
Informed Consent  
8. Subject is capable of giving signed informed consent as described in Appendix 1/ 
Section  10.1 , which includes compliance with the requirements and restrictions listed in 
the ICF and in this protocol . 
5.2. Exclusion Criteria  
Subject s are excluded from the study if any of the following criteria apply:  
Medical Conditions  
1. Subject has evidence or history of clinically significant acute or chronic disease, or clinically significant illness within 30  days of the Screening Visit.  
2. Subject has a history of clinically significant hypersensitivity or allergies to any of the 
inactiv e ingredients contained in the active or placebo drug products. 
3. Subject has a history of any condition that would interfere with their ability to receive an enema.  
4. Subject has a recent history of anal fissure, anal abscess, complicated hemorrhoids, active proctitis, or presence or history of ulcerative colitis or Crohn's disease.  
Prior/Concomitant Therapy  
5. Subject has used a prescription medication during the 14 days before Check -in (Day  ‑1). 
Use of prescription medication, unless necessa ry to treat a medical emergency, is 
excluded during the study until after the Follow-up Phone Call on Day 21. 
6. Subject has used any over- the-counter medications, including laxatives, during the 7 days 
before Check- in (Day  ‑1). Use of over- the-counter medica tion, including laxatives, is not 
permitted during the study until after Discharge on Day  8. (Note: Acetaminophen may be 
used at the investigator’s discretion, in consultation with the sponsor, as per Section  6.5.) 
7. Subject has used vitamins , dietary, or herbal supplements from 7  days before Check -in 
(Day  ‑1). Use of these supplements is not permitted during the study until after Discharge 
on Day 8. 
8. Subject has received a licensed vaccine during the 14  days before Check- in (Day  ‑1) or is 
planning to receive any vaccine during the study (up to the Follow-up Phone Call on Day 21). 
9. Subject has received blood products during the 2 months before Check- in (Day ‑1). 
10. Subject has undergone a surgical procedure during the 30 days before Check -in (Day  ‑1), 
other than minor dermatologic procedures, or has a history of any surgery involving the 
Protocol C3300-102 
25 GI tract or anal canal (with the exception of endoscopic procedures, ap pendectomy, and 
cholecystectomy). 
Prior/Concurrent Clinical Study Experience  
11. Subject has received any investigational drug or vaccine during the 30 days or
5 half ‑lives of that investigational drug (whichever is longer) before the Screening Visit,
or is planning to receive another investigational drug at any time during the study (up to
the Follow-up Phone Call on Day 21 ).
Diagnostic A ssessments 
12. Subject has a 12- lead ECG demonstrating severe bradycardia (heart rate <40 beats per
minute) or average QTcF ≥450 msec for males and ≥470 msec for females at theScreening Visit or at Check -in on Day ‑ 1.
13.Subject has elevated (>1.5  times the upper limit of normal as defined by the laboratory)
levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine,or bilirubin at the Screening Visit or at Check -in on Day ‑ 1.
14. Subject has confirmed or suspected infection with SARS‑CoV‑2 (COVID‑ 19) at the
Screening Visit or Check -in on Day ‑ 1, or was diagnosed with COVID‑19 or had contact
with a person with  COVID‑19 within 14 days of the Screening Visit.
15.Subject has positive serology for human immunodeficiency virus (HIV) ‑1, HIV ‑2, or
hepatitis B surface antigen (HBsAg), or positive for anti- HIV‑ 1, anti- HIV‑ 2, or
anti‑hepatitis C virus (HCV) antibodies at the Screening Visit.
16. Identification of an anatomical abnormality upon Screening rectal examination which
will make enema administration difficult.
Other Exclusions 
17. Subject has a history of difficulty receiving an enema.
18. Subject has a history of alcohol or drug addiction during the year before the Screening
Visit, or has a positive drug or alcohol screen at the Screening Visit or Check -in on
Day ‑1.
19. Subject has ingested any alcohol-containing foods or beverages during the 48 hours
before Check- in (Day  ‑1). Ingestion of alcohol -containing foods or beverages is excluded
during the study until after the Follow -up Phone Call on Day 21.
20. Subject has donated blood products during the 6 weeks before Check -in (Day  ‑1).
21. Subject is involved in the conduct and administration of this study as an investigator,
subinvestigator, study coordinator, other study staff, or sponsor staff.
Protocol  C3300-102 
 26  
    5.3. Lifestyle Considerations  
5.3.1. Meals and Dietary Restrictions  
1. Subjects agree to refrain from starting a new diet during the study as described in 
Section  5.1. 
2. Subjects will fast for at least 6 hours prior to dos ing on Day  1 and for at least 1  hour 
following dosing as described in  Section  6. During this time, w ater is permitted . 
5.3.2. Caffeine, Alcohol, and Tobacco 
1. Subjects will abstain from ingesting any alcohol-containing foods or beverages from  
48 hours before Check- in (Day  ‑1) unt il after the Follow -up Phone Call  on Day  21 as 
described in Section  5.2. 
2. Subject s are permitted to ingest  caffeine- or xanthine- containing products ( eg, coffee, tea, 
cola drinks, and chocolate) , but should limit intake to ≤ 3 cups per day. 
3. Subjects who use tobacco products will be instructed that use of nicotine-containing products (including nicotine patches) will not be permitted while they are in the CRU. 
5.3.3. Activity  
1. Subjects agree to refrain from making any new or major lifestyle changes (eg, exercise 
regimen) as described in Section  5.1. 
2. Subjects must follow contraception requirements outlined in Section  5.1. 
3. Prior to d osing, subjects will be encouraged to empty their bowels, if possible. 
4. After dosing, subjects will lie on their left side for at least 3 0 minutes (including for vital 
signs collection), followed by at least 30 additional minutes in the semi supine position as 
outlined in  Section  6.1.1. Subjects should avoid using the bathroom and hold in the 
enema for at least 1 hour. 
5. For vital sign  collection  during the Clinic Period, positional and activity restrictions at 
each timepoint are noted in th e SoA ( Table  1) and Section  8.2.2. 
5.4. Screen Failures  
Screen failures are defined as subject s who consent to participate in the clinical study but are not 
subsequently randomized. A minimal set of screen failure information is re quired to ensure 
transparent reporting of screen failure subject s to meet the Consolidated Standards of Reporting 
Trials ( CONSORT ) publishing requirements and to respond to queries from r egulatory 
authorities. Minimal information includes demography, scree n failure details, eligibility criteria, 
and any SAE . 
Individuals who do not meet the criteria for participation in this study (screen failure)  may  be 
rescreened  following consultation with the sponsor . Rescreened subjects should be assigned a 
separate subject  number for each screening ; once a subject number has been assigned it must not 
be reused . 
Protocol  C3300-102 
 27  
    6. STUDY INTERVENTION  
Study intervention  (also referred to as “study drug”) is defined as an y investigational 
intervention (s), and may include marketed product(s) or placebo, intended to be administered to 
a study subject  according to the study protocol. 
The study will evaluate multiple -ascending doses of IW ‑3300 in a double-blind manner. The 
9 subjects within each cohort will be randomized to receive multiple doses of IW ‑3300 
(6 subjects) or placebo (3 subjects), administered rectally (as a low -volume [2 0 mL] enema) 
following a fast of at least 6 hours. The planned cohorts are: 
• Cohort 1: IW ‑3300 100 μg or matching placebo rectal dose once daily  
• Cohort 2: IW ‑3300 300 μg or matching placebo rectal dose once daily  
• Cohort 3 (optional): IW ‑3300 >100 μg but <300 μg or matching placebo rectal dose 
once daily (decision to enroll this cohort will be determined after safety reviews of 
previous cohorts, in the case of intolerability at 30 0 μg but tolerability at 100 μg)  
Dosing in Cohort 2 and optional Cohort 3 will only proceed following a review of safety data 
from the previous cohort(s) , including AEs, clinical laboratory test results, vital signs, and 
12‑lead ECGs. The determination of dose escalation will be made at a meeting of the Dose 
Escalation Committee.  
Treatment duration will be 7 days; subjects will be followed in the Phase  1 CRU for the duration 
of dosing, until at least 24 hours after the last d ose of study drug and contacted by phone for 
follow -up approximately 2 week s after the last dose. Total subject participation will be 29 to 
57 days, including the Screening, Clinic, and Follow-up Periods. 
Protocol  C3300-102 
 29  
    moisture and light and stored between ‑ 25°C to ‑15°C. Prior to compounding, IW ‑3300 drug 
substance will be thawed for a minimum of 3 0 minutes prior to use. 
The investigational drug product may be compounded on the day of administration and stored at 
room temperature prior to dosing (continuous mixing not required). If the investigational drug product is stored for more than 24 hours, it must be stored refrigerated (2  C to 8°C) for no longer 
than the product shelf life. Refrigerated drug product must be equilibrated to room temperature for at least 3 0 minutes prior to dosing. Compounding and storage of the drug product must occur 
in accordance with the instructions provided in the Pharmacy Manual . Specifically designated 
unblinded CRU pharmacy staff will be responsible for preparing dosing for each cohort and providing doses to the study coordinator to administer to subj ects (see Section  6.1.1 for dosing 
instructions).  
Storage and accountability of study drug should adhere to the following: 
1. The investigator or designee must confirm appropriate temperature conditions have been maintained during transit for all study drug received and any discrepancies are reported 
and resolved before use of the study drug. 
2. Only subjects enrolled in the study may receive study drug and only authorized site staff 
may supply or administer study drug. All study drug must be stored in accordance with 
the labeled storage conditions. 
3. The investigator, institution, or the head of the medical institution (where applicab le) is 
responsible for study drug accountability, reconciliation, and record maintenance ( ie, 
receipt, reconciliation, and final disposition records).  
4. Further guidance and information for the final disposition of unused study drug are 
provided in the  Pharm acy Manual . 
6.3. Measures to Minimize Bias: Randomization and Blinding  
6.3.1. Randomization 
The subject identification (SID) number will be assigned in an ascending sequential order (eg, beginning with 001, 002, etc.) at the time the subject signs the ICF . The subject will retain the 
same unique SID number throughout the Clinic and Follow-up Periods. 
Subjects who meet all of the inclusion criteria and none of the exclusion criteria will be  
randomized into the study on Day  1. A total of up to 27 subjects  (up to 3 cohorts of 9 subjects 
each)  will be randomized in a 2:1 ratio to receive IW ‑3300 (N=6) or placebo  (N=3), for each 
cohort, as detailed in Section  6.1. Randomization numbers encoding the subjects’ treatment 
assignment s will be based on a randomization schedule that is computer-generated prior to the 
study, by an independent statistician  from the CRO who is not otherwise associated with the 
study. The randomiz ed treatment  allocation  for each subject will be contained in a sealed, opaque 
envelope opened at the time of the subject’s randomization. 
6.3.2. Blinding  
The investigator and all other CRU staff , sponsor study personnel , and the subject will remain  
blinded to individual subject treatment assignments th roughout the study, except as noted below. 
Protocol  C3300-102 
 30  
    The Dose Escalation Committee, which will include sponsor and CRO representatives, will 
conduct blinded reviews of all the safety/tolerability parameters of the dosing cohort through 
Discharge ( Day 8) in order to make decisions regarding subsequent dosing. 
Specific designated personnel in the Ironwood Global Patient Safety Group may be unblinded to 
the treatment assignment of individual subjects for regulatory  reporting purposes. All other 
sponsor study personnel, except as described, will remain  blinded until the study is complete and 
the database is locked, unless warranted by emerging  safety or tolerability issues.  
Specifically designated unblinded CRU pharmacy staff will be responsible for preparing dosing 
for each cohort and providing doses to the study coordinator to administer to subjects. The 
investigator (except as detailed in the next paragraph) and the remaining CRU staff will be blinded as to treatment.  In the event of a Quality Assuranc e audit, the auditor(s) will be allowed 
access to unblinded study intervention records at the CRU to verify that randomization/dispensing has been done accurately. 
Site unblinding of a subject’s treatment assignment is restricted to emergency situations  that 
necessitate identifying the study drug for the welfare of the subject. Subject safety must always 
be the first consideration in making such a determination. If  the investigator decides that 
unblinding is warranted, the investigator, or person designated by the investigator, should contact 
the sponsor’s m edical monitor directly to discuss the need for emergency unblinding. Individual 
sealed unblinding envelopes, which can be opened to identify the treatment assignment for an 
individual subject in an emerg ency, will be provided to and retained by the CRU pharmacist. The 
reason for breaking the blind will be recorded. 
6.4. Study Intervention Compliance 
Subjects will receive study drug directly from the investigator or designee, under medical 
supervision. The date and time of each dose administered in the clinic will be recorded in the 
source documents and recorded in the e CRF.  The dose of study drug and study subject 
identification will be confirmed at the time of dosing by a member of the CRU staff other than 
the person administering the study intervention.  
6.5. Concomitant Therapy  
Subject s must abstain from taking prescription medications during the 14 days before Check -in 
(Day ‑1) until after completion of the Follow -up Phone Call on Day  21; over- the-counter 
medications  (including laxatives, vitamins , and dietary or herbal supplements) during the 7 days 
before Check-in ( Day ‑1) until after Discharge on Day  8; and licensed vaccines during the 
14 days before Check -in (Day ‑1) until after completion of the Follow -up Phone Call on Day  21. 
Acetaminophen at doses of ≤ 3 grams/day is permitted for use during the study at the 
investigator’s discretion , in consultation with the m edical monitor. 
Any medication (including over- the-counter or prescription medicines, vitamins, and/or herbal 
supplements) or vaccine that the subject is receiving at the time of Screening or receives during 
the study must be recorded along with: 
• Reason for use 
• Dates of administration , including start and end dates  
Protocol  C3300-102 
 31  
    • Dosage information , including dose and frequency 
The m edical monitor should be contacted if there are any questions regarding concomitant or 
prior therapy. 
6.5.1. Rescue Medicine  
Not applicable to  this study of healthy subjects 
6.6. Dose Modification  
The decision to proceed to the 300 ‑μg dose level of IW ‑3300 (Cohort 2) will be made by the 
Dose Escalation Committee, based on blinded safety and tolerability data obtained through 
Discharge on Day  8 in all subjects at the 100 ‑μg dose level (Cohort 1). The decision to proceed 
with an optional 3rd cohort will be made by the Dose Escalation Committee based on blinded safety and tolerability data for both Cohorts  1 and 2. The dose will be IW‑3300 >100 μg but 
<300 μg.  
Dosing at a given dose level may be temporarily suspended for any of the reasons listed in Section  7.1.1. 
6.7. Intervention A fter the End of the Study  
There is no study intervention following the end of the study. 
Subjects with ongoing AEs or other safety concerns will be followed until resolution or until no 
further queries or follow -up actions are required ; at the discretion of the investigator, subjects 
with ongoing safety concerns may have discharge delayed if necessary for continued monitoring . 
Protocol C3300-102 
32 7. DISCONTINUATION OF STUDY INTERVENTION AND
SUBJECT  DISCONTINUATION/WITHDRAWAL
7.1. Discontinuation of Study Intervent ion
It may be necessary for a subject to permanently discontinue study drug. A subject will be 
discontinued from study drug in the event of: 
•A confirmed pregnancy
•A SAE considered by the investigator or Sponsor to be related to study drug
Dosing of study drug for an individual subject may be suspended temporarily as detailed in 
Section  7.1.1; if the subject is unable to resume dosing, they should follow the instructions for 
permanent discontinuation below. 
If study drug is permanently discontinued, then the subject will have the safety evaluations 
scheduled for Discharge ( Day 8) performed. See the SoA ( Table  1) for data to be collected at the 
time of discontinuation and follow-up, and for any further evaluations that need to be completed. 
If a subject is discontinuing study drug due to an AE, the AE must be followed until it is 
resolved, stable, or judged by the investiga tor to be not clinically significant.  
7.1.1. Study Suspension or Termination  
Dosing may be temporarily suspended for either dose level if any of the following occur within a 
cohort: 
•≥1 subject with an SAE considered related to study drug
•≥1 subject with a n National Cancer Institute Common Terminology Criteria for
Adverse Events ( NCI-CTCAE) Grade  3 or higher AE considered related to study
drug (CTCAE v5.0 will be used; grading criteria are summarized in Appendix 3/Section  10.3.3.2)
•≥3 subjects with CTCAE Grade  2 or higher AEs considered related to study drug
The Dose Escalation Committee should consider the benefit -risk ratio in their determination to 
suspend dosing temporarily or permanently. If the benefit- risk ratio is considered unacceptable 
and the effect related to active study drug by the Dose Escalation Committee, dosing at a given 
dose level will be stopped, and no additional cohorts will be dosed at the same or higher dose 
level (a lower dose could still be studied).  
The sponsor may permanently terminate the study, or a component of the study, at any time. 
Reasons for termination may include, but are not limited to:  
•Death, SAE, or other safety finding considered to be related to IW ‑3300 that may
preclude further dosing
Protocol  C3300-102 
 33  
    7.2. Subject Discontinuation/ Withdrawal from the Study  
• A subject  may withdraw from the study at any time at his/her own request or may be 
withdrawn at any time at the discretion of the investigator for safety, behavioral, 
compliance, or administrative reasons . This is expected to be uncommon. 
• At the time of discontinuation  from the study, if possible, an ET visit should be 
conducted, as shown in the SoA ( Table  1). See  the SoA for data to be collected at the 
time of study discontinuation and follow-up and for any further evaluations that need 
to be completed. 
• The subject will be permanently discontinued both from the study intervention and from the study at that time.  
• If the subject  withdraws consent for disclos ure of future information, the s ponsor may 
retain and continue to use any data collected before such a withdrawal of consent. 
• If a subject  withd raws from the study, he/she may request destruction of any samples 
taken and not tested, and the investigator must document this in the site study records. 
7.3. Lost to Follow -up 
A subject  will be considered lost to follow -up if he or she repeatedly fails to return for scheduled 
visits and is unable to be contacted by the study site. 
The following actions must be taken if a subject  fails to return to the clinic for a required study 
visit:  
• The site must attempt to contact the subject, reschedule the missed visit as soon as 
possible, counsel the subject  on the importance of maintaining the assigned visit 
schedule, and ascertain whether or not the subject  wishes to and/or should continue in 
the study. 
• Before a subject  is deemed lost to follow -up, the investigator or designee must make 
every effort to regain contact with the subject (where possible, 3 telephone calls and , 
if necessary , a certified letter to the subject’s last known mailing address or local 
equivalent methods). These contact attempts should be docume nted in the subject ’s 
medical record . 
• Should the subject continue to be unreachable, he/she will be considered to have 
withdrawn from the study  and reason for discontinuation will be “lost to follow-up.” 
Discontinuation of the  site or of the study as a whole are handled as part of Appendix 1/ 
Section  10.1 . 
Protocol  C3300-102 
 34  
    8. STUDY ASSESSMENTS AND PROCEDURES  
• Study procedures and their timing are summarized in the SoA ( Table  1). Protocol 
waiver s or exemptions are not allowed. 
• Immediate  safety concerns should be discussed with the sponsor immediately upon 
occurrence or awareness to determine if the subject  should continue or discontinue 
study drug. 
• Adherence to the study design requirements, including those specified in the SoA 
(Table  1), is essential and r equired for study conduct. 
• All screening evaluations must be completed and reviewed to confirm that potential 
subject s meet all eligibility criteria. The investigator will maintain a screening log to 
record details of all subjects screened and to confirm e ligibility or record reasons for 
screening failure, as applicable.  
8.1. Efficacy Assessments  
Efficacy will not be evaluated in this Phase 1 study in healthy subjects. 
8.2. Safety Assessments  
Planned timepoints for all safety assessments are provided in the SoA ( Table  1). 
8.2.1. Physical Examination s 
Physical examination s will be performed as outlined in the SoA ( Table  1), by the investigator or 
a licensed health professional listed on Form FDA 1572. 
• A complete physical examination will include, at a minimum, assessments of the  
general appearance of the subject and the HEENT (head, eyes, ears, nose, and throat), 
cardiac, respiratory, gastrointestinal, musculoskeletal, neurological, and 
dermatological systems.  
• Rectal examination at all tim epoints should include a digital rectal examination and 
visual inspection of the perianal area for redness or irritation. If significant redness, rectal pain, fever, bleeding, or mucus is observed, anoscopy may be performed as part of the rectal examinatio n. 
• On Days  1 through 7, the physical examination will be symptom-directed and 
conducted prior to study drug administration. 
• Height and weight will also be measured and recorded at the timepoints noted in the  
SoA (Table  1). 
• Investigators should pay special attention to clinical signs related to previous serious illnesses, which will be reason for exclusion from the study. 
• Any physical examination abnormalit y that the investigator considers to be 
potentially clinically significant and changed from baseline will be reported as an AE. 
Protocol  C3300-102 
 35  
    8.2.2. Vital Signs  
Vital signs will be performed as outlined in the SoA  (Table  1). 
• Vital signs will include oral temperature, blood pressure, and pulse rate.  
• Blood pressure and pulse measurements will be assessed  with a complet ely 
automated device. Manual techniques will be used only if an automated device is not 
available.  
• In a semi supine position, blood pressure and pulse will be obtained at the 0.5-hour 
postdose timepoint on Days  1 and 7 (consistent with the position required following 
dosing). 
• Blood pressure and pulse at the 2-, 4-, and 8-hour postdose timepoints on Days  1 and 
7, as well as predose on Days  3 through 6, should be preceded by at least 5 minutes of 
rest for the subject in a quiet setting without distractions (e g, television, cell phones).  
• At all other timepoints (ie, Day 1 predose and 1- and 6- hours postdose, Day 2 
predose, Day  7 predose and 1- and 6-hours postdose, and Day  8 [24‑ hours post- Day 7 
dose]), orthostatic blood pressure and pulse measurements will be obtained . Subjects 
must lie quietly for ≥5 minutes before supine/semisupine blood pressure and pulse measurements are taken, then assume standing position for 3  minutes before standing 
blood pressure and pulse measurements are taken. I f a subject has orthostatic 
symptoms upon standing (eg, palpitation, dizziness), they will be assisted and asked to lie down without waiting the 3 minutes for vital sign assessment. Orthostatic 
measurements may be taken at other vital signs collection time points if clinically 
indicated, at the discretion of the investigator.  
• When applicable, vital signs measurements will be obtained before blood draws.  
8.2.3. Electrocardiograms  
• Triplicate  12-lead ECG will be obtained as outlined in the SoA ( Table  1) using an 
ECG machine that automatically calculates the heart rate and measures of PR, QRS, 
QT, and QTcF int ervals.  
• ECGs should be obtained after the subject has been s upine for at least 5 minutes. 
• At each time point at which triplicate ECG s are required, 3 individual ECG tracings 
should be obtained as closely as possible in succession, but no more than 2 minutes apart. The full set of triplicates should be completed in less than 4 minutes . 
8.2.4. Clinical Safety Laboratory Assessments  
• See Appendix 2/ Section  10.2 for the list of clinical laboratory tests to be performed 
and the SoA ( Table  1) for the timing and frequency. All protocol-required laboratory 
assessments must be conducted in accordance with the laboratory manual and the 
SoA.  
Protocol  C3300-102 
 36  
    • The investigator must review the laboratory report, document this review, and record 
any clinically re levant changes occurring during the study in the AE section of the 
eCRF. The laboratory reports must be filed with the source documents. 
• All laboratory tests with values considered clinically significantly abnormal during participation in the study or within 14 days after the last dose of study drug  should be 
repeated until the values return to normal or baseline or are no longer considered clinically significant by the investigator or medical monitor.  
− If such values do not return to normal/baseline within a period of time judged 
reasonable by the investigator, the etiology should be identified and the sponsor 
notified. 
− If laboratory values from non-protocol- specified laboratory assessments 
performed at the institution’s local laboratory require a change in subject  
management or are considered clinically significant by the investigator (eg , SAE 
or AE or dose modification), then the results mu st be recorded in the e CRF.  
8.2.5. Bladder and Bowel Movement Diary  
The BBMD will be completed in accordance with the instructions in the SoA ( Table  1). 
Subjects will enter BM -related information into a paper diary, the BBMD, on an event-driven 
basis (ie, following each BM) . The BM -related information will include the day and time of BMs 
and a report of stool consistency for each BM using the BSFS ( 8); BSFS (1=Separate hard lumps 
like nuts [difficult to pass] to 7=Watery, no solid pieces [entirely liquid]).  
Subjects will enter bladder information into the BBMD, which will include the following 
questions: 
In the past 24 hours… 
• Did you have to urinate more frequently than normal? (yes/no) 
• How many times did you urinate? (0  to 2; 3 to 6; 7  to 10; or 10+ times)  
• Did you feel the strong need to urinate with little or no warning? (yes/no) 
• Did you have to get up to urinate during the night more frequently than usual? (yes/no) 
• How many times did you have to get up at night to urinate? (0, 1, 2, 3+ times) 
• Did you have pain or burning in your bladder or pelvic area? (yes/no) 
8.3. Adverse Events and Serious Adverse Events 
The definitions of AEs and SAE s can be found in Appendix 3/ Section  10.3. 
AEs will be reported by the subject (or, when appropriate, by a caregiver, surrogate, or the 
subject 's legally authorized representative) . 
The investigator and any  qualified  designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible for following 
Protocol  C3300-102 
 37  
    up AEs that are serious, considered related to the study intervention  or study procedures, or that 
caused the subject to discontinue study  drug (s ee Section  7). 
8.3.1. Time P eriod and Frequency for C ollecting AE and SAE Information  
All AE s and SAEs  will be collected from the signing of the ICF  until completion of study 
participation (ie, early termination or Follow -up Phone Call) at the timepoin ts specified in the 
SoA ( Table  1). 
Any medical condition that is present at the time that a randomized subject is screened and does 
not deteriorate (worsen in severity and/or frequency) should be recorded as Medical History and not as an AE. However, if the s ubject’s condition deteriorates at any time during the study, it will 
be recorded as an AE. AEs characterized as intermittent require documentation of onset and duration of each episode. Pretreatment AEs will be collected and captured in the subject’s source documentation from the time the subject signs the ICF until the subject receives study drug. 
Pretreatment AEs in randomized subjects will additionally be entered on the AE page of the 
subject’s eCRF. Laboratory abnormalities, changes in vital signs, and physical examination findings should be considered AEs and reported on the AE page of the subject's eCRF only if the 
investigator considers them clinically significant and/or they necessitate intervention.  
All SAE s will be recorded and reported to the sponsor or designee immediately and under no 
circumstance should this exceed  24 hours, as indicated in Appendix 3/ Section  10.3. The 
investigator will submit any updated SAE data to the sponsor within 24 hours of it being 
available.  
Investigators are no t obligated to actively seek AEs or SAE s after the conclusion of study 
participa tion. However, if the investigator learns of any SAE, including a death, at any time after 
a subject has been discharged from the study, and he/she considers the event to be reasonably 
related to the study intervention  or study participation, the investigator must promptly notify the 
sponsor. 
8.3.2. Method of Detecting AE s and SAE s 
The method of recording, evaluating, and assessing causality of AE s and SAE s, and the 
procedures for completing and transmitting SAE reports are provided in Appendix 3/ 
Section  10.3 . 
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended and 
nonleading verbal questioning of the subject is the preferred method to inquire about AE  
occurrences. 
8.3.3. Follow- up of AE s and SAE s 
After the initial AE/SAE report, the investigator is required to proactively follow each subject at 
subsequent visits/contacts. Subjects with ongoing AEs or other safety concerns will be followed 
until resolution or until no further queries or follow -up actions are required. All SAEs  will be 
followed until resolution, stabilization, the event is otherwise explained, or the subject  is lost to 
follow -up (as defined in Section  7.3). Further information on follow -up procedures is provided in 
Appendix 3/S ection  10.3.3. 
Protocol  C3300-102 
 39  
    8.4. Treatment of Overdose  
For this study, any dose that exceeds the dosage or frequency specified in the protocol will be 
considered an overdose. 
The sponsor does not recommend specific treatment for an overdose. In the event of an overdose, the investigator should: 
1. Report any case of overdose to the sponsor and use their clinical judgment to treat the 
case of overdose as needed with the appropriate general supportive measures. Subjects will be monitored for potential development of diarrhea and dehydration and, if present, 
will be managed accordingly. 
2. Document the quantity of the excess dose as well as the duration of the overdose in the 
CRF.  
8.5. Pharmacokinetics  
Blood for the determination of IW ‑3300 and metabolites in plasma will be collected from all 
dosed subjects during the Clinic Period at timepoints specified in the SoA ( Table  1). Instructio ns 
for the collection and handling of biological samples will be provided by the sponsor . The actual 
date and time (24- hour clock time) of each sample will be recorded.  
The following PK parameters will be calculated using a noncompartmental approach if a 
sufficient number of plasma samples exist above lower limit of quantification:  
• Area under the plasma concentration time curve from time zero to the time at which 
the last measurable concentration is observed (AUC 0-t) 
• Area under the plasma concentration time curve from time zero to time infinity (AUC
0-∞) 
• Maximum plasma concentration (C max) 
• Time to maximum plasma concentration (T max) 
• Terminal elimination half- life (t 1/2) 
Blood samples will be analyzed in a single batch after all subjects have completed the study . No 
individual drug concentration information will be shared until the study has been unblinded. 
8.6. Microbiome 
Gut microbiome will be assessed using stool samples collected in accordance with the SoA 
(Table  1). At Check -in/Day ‑1, the subject will bring in a stool sample using the sample 
collection kit issued by the site. Between Day  7 (postdose) through Day  8 (predischarge), the 
first stool passed will also be collected. If no stool is passed during this time, the subject will be discharged with a stool collection kit and asked to return the sample to the CRU. 
The stool collection kit is a tube that contains DNA stabilizer. An aliquot of stool (approximately 
1 teaspoonful) will be added to the tube and frozen for analysis. 
Protocol  C3300-102 
 40  
    8.7. Pharmacodynamics 
Pharmacodynamics are not evaluated in this study.  
8.8. Genetics  
Genetics are not evaluated in this study ; no samples will be collected for genetics research.  
8.9. Biomarkers  
Biomarkers are not evaluat ed in this study; no samples will be collected for biomarker research.  
8.10. Immunogenicity Assessments 
Immunogenicity is not evaluated in this study; no samples will be collected to evaluate 
antibodies to IW ‑3300. 
8.11. Medical Resource Utilization and Health Economics 
Medical resource utilization and health economics parameters are not evaluated in this study. 
Protocol C3300-102 
41 9. STATISTICAL CONSIDERATIONS
9.1. Statistical Hypotheses
No hypothesis testing i s planned.  
9.2. Sample Size Determination  
No statistical sample size determination process was performed. The sample size chosen for each 
cohort (9 subjects) is considered sufficient for evaluation of safety, tolerability, PK, and 
micro biome. 
9.3. Populations for Analyses  
The following populations are defined: 
Population  Description  
Screened Set  The Screened Set consists of all subjects who have signed 
informed consent.  
Intent -to-treat  Set The Intent -to-treat Set consists of all subjects in the Screened Set 
who have been randomized to a treatment regimen. Analysis will 
be performed according to the allocated treatment regimen regardless of the treatment regimen actually received.  
Safety Analysis Set  The Safety Analysis Set consists of all subjects who receive an y 
amount  of study drug. Analysis will be performed according to the 
treatment actually received regardless of the allocated treatment.  
PK Analysis Set  The PK Analysis Set consists of all subjects in the Safety Analysis Set who have at least 1 postdose PK assessment. Analysis will be 
performed according to the treatment actually received regardless of the allocated treatment.  
Microbiome Analysis S et The Microbiome Analysis Set consists of all subjects in the Safety Analysis Set who have at least 1 postdose microbiome 
assessment. Analysis will be performed according to the treatment actually received regardless of the allocated treatment.  
9.4. Statistical Analyses  
The statistical analysis plan ( SAP) will be finalized prior to  the clinical database lock and will 
include a more technical and detailed description of the statistical analyses described in this 
section . 
9.4.1. General C onsiderations 
For summaries by treatment group, data from subjects who receive placebo in different cohorts 
can be combined and presented as one treatment group (referred to as “treatment” and 
“placebo”), as appropriate.  
Continuous variables will be summarized using descriptive statistics (N, mean, SD, median, 
minimum, and maximum). Categorical variables will be summarized using th e count and 
Protocol  C3300-102 
 42  
    proportion of subjects in each category. Furthermore, PK data will be summarized using 
descriptive statistics, geometric mean, and coefficient of variation (CV%) of the geometric mean.  
9.4.2. Primary  Endpoints  Analys es 
The primary endpoint analysis wi ll be based on the Safety Analysis Set.  
AE verbatim terms will be coded in the electronic data capture (EDC) system against the most current version of the Medical Dictionary for Regulatory Activities (MedDRA) available at the 
start of the study. 
TEAEs are defined in Section  10.3.1. The TEAEs and TESAEs for 1  calendar day post last dose 
will be summarized by system organ class, preferred term, and treatment (or cohort).  
9.4.3. Secondary  Endpoint  Analysis 
Not applicable to this study 
9.4.4. Exploratory Endpoints Analys es 
PK analyses will be based on the PK Analysis Set.  
Plasma concentrations of IW‑3300 and metabolites will be summarized by treatment (or cohort) 
at each assessment timepoint; additionally, a listing of plasma concentrations will be provided. 
PK parameters ( listed  in Section  8.5) will also be calculated for each subject and summarized by 
treatment, if systemic levels of IW ‑3300 and/or metabolites are measurable/as data permit  
(≥1 plasma concentration above the lower limit of quantitation [LLOQ] is necessary for 
calculation of C
max and T max; ≥3 plasma concentrations above LLOQ are necessary for 
calculation of AUC 0-t, AUC 0‑∞, and t 1/2). Otherwise, the levels of IW‑3300 and/or metabolites 
will not be included for the analysis. 
The analysis of the microbiome at the genus level will be based on the Microbiome Analysis Set.  
The relative abundance of different phyla, class, order, family, and genera will be constructed 
and summarized by treatment (or cohort) at baseline and following 7 days of study drug 
administration using descriptive statistics. Changes from baseline will be calculated.  
9.4.5. Safety Analys es 
All safety analyses, including the BBMD analyses, will be based  on the Safety Analysis Set . 
Summaries for the safety parameters co rresponding to the primary endpoints (including TEAEs  
and TESAEs) are described in Section  9.4.2. Additionally, listings will be provided for severe 
AEs, drug-related AEs, SAEs, and AEs leading to study discontinuation. 
Descriptive statistics and changes from baseline at each assessment timepoint will be presented 
by treatment (or cohort) for the Clinic Period for:  
• Clinical laboratory values (in  standard units) for each hematology, chemistry, 
inflammatory marker, and urinalysis parameter  
• Vital signs (ie, pulse rate, systolic and diastolic blood pressure , oral temperature, and 
body weight) 
Protocol  C3300-102 
 43  
    • ECG parameters (ie, heart rate and measures of PR, QRS, QT , and QTcF intervals) 
− Additionally, the overall 12- lead ECG interpretation (normal, abnormal not 
clinically significant, or abnormal clinically significant) will be summarized.  
For the BBMD parameters, d escriptive statistics at each assessment timepoint will be presented 
by treatment (or cohort) for each study period (Screening Period and Clinic Period) : BM 
frequency, stool consistency, fecal incontinence, urinary frequency, urinary urgency, nocturia, 
and bladder/pelvic pain. 
BM-related b aseline values will  be derived from the BBMD data collected in the Screening 
Period, specifically, the period of time from 7 days prior to Check- in up to the time of 
randomization on Day  1. Bladder- related baseline values will be derived fr om the BBMD data 
collected predose on Day  1 (with a 24 -hour recall). The Clinic Period BM - and bladder- related 
values will be derived from the BBMD data collected after randomization in the Clinic Period, 
specifically, the period of time from Day 1 (postrandomization) through Day 8 (Dischar ge). 
9.4.6. Other Analysis/Analyses 
Not applicable to this study 
9.5. Interim Analyses  
No interim analysis is planned for the study. Interim safety reviews are detailed in Section  6.6. 
9.6. Data Monitoring Committee (DMC)  
This study will not utilize a DMC. A Dose Escalation Committee will be utilized to review safety data for each cohort in order to make decisions about dose escalation, as described in Section  6.6. 
Protocol  C3300-102 
 44  
    10. SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS  
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations  
10.1.1. Regulatory and Ethical Considerations 
This study will be conducted in accordance with the protocol and with the following: 
• Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and  Council for International Organizations of Medical 
Sciences (CIOMS) International Ethical Guidelines  
• Applicable ICH GCP Guidelines  
• Applicable laws and regulations 
The protocol, protocol amendments, ICF, IB , and other relevant documents ( eg, advertisements ) 
must be submitted to an IRB/IEC by the investigator and reviewed and approved by the IRB/IEC before the study is initiated. 
Any amendments to the protocol will require IRB/IEC approval before implementation of 
changes made to the study design, except for changes necessary to eliminate an immediate 
hazard to study subject s. 
The investigator will be responsible for the following: 
• Providing written summaries of the status of the study to the IRB/IEC annually or more frequently in accordance with the requirements, policies, and procedures established by the IRB/IEC  
• Notifying the IRB/IEC of SAEs or other significant safety findings as required by IRB/IEC procedures  
• Providing oversight of the conduct of the study at the site and adherence to 
requirements of 2 1 CFR, ICH guidelines, the IRB/IEC, European regulation 
536/2014 for clinical studies (if applicable), and all other applicable local regulations  
10.1.2. Financial Disclosure  
Investigators and subinvestigators will provide the sponsor with sufficient, accurate financ ial 
information as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory authorities. Investigators are responsible for providing information on financial interests during the course of the study and for 
1 year after completion of the study.  
10.1.3. Informed Consent Process  
The investigator or his/her representative will explain the nature of the study to the subject or 
his/her legally authorized representative and answer all qu estions regarding the study. 
Protocol  C3300-102 
 45  
    Subject s must be informed that their participation is voluntary. Subject s or their legally 
authorized representative will be required to sign a statement of informed consent that meets the 
requirements of 2 1 CFR Part  50, local regulations, ICH guidelines, Health Insurance Portability 
and Accountability Act (HIPAA) requirements, where applicable, and the IRB/IEC or study 
center.  
The medical record must include a statement that written informed consent was obtained before the subj ect was enrolled in the study and the date the written consent was obtained. The 
authorized person obtaining the informed consent must also sign the ICF. 
Subject s must be reconsented to the most current version of the ICF(s) during their participation 
in the study. 
A copy of the ICF(s) must be provided to the subject  or the subject’s legally authorized 
representative.  
Subject s who are rescreened are required to sign a new ICF.  
10.1.4. Data Protection 
All parties will comply with all applicable laws, including laws regarding the implementation of 
organizational and technical measures to ensure protection of participant data.  
Subjects will be assigned a unique identifier by the sponsor. Any subject records or datasets that 
are transferred to the sponsor  will contain the identifier only; subject names or any information 
which would make the subject identifiable will not be transferred.  
The subject must be informed that his/her personal study -related data will be used by the sponsor 
in accordance with loca l data protection law s. The level of disclosure must also be explained to 
the subject  who will be required to give consent for their data to be used as described in the ICF.  
The subject must be informed that his/her medical records may be examined by c linical quality 
assurance auditors or other authorized personnel appointed by the sponsor, by appropriate 
IRB/IEC members, and by inspectors from regulatory authorities.  
10.1.5. Committee Structure  
Key study personnel , including sponsor  and CRO representatives, and their contact details will 
be provided prior to the Site Initiation Visit.  
The safety of this study will be closely monitored on an ongoing basis by sponsor 
representatives.  A Dose Escalation Committee composed of sponsor and CRO representatives 
will make decisions about dose escalation, as detailed in Section  6.6. 
10.1.6. Dissemination of Clinical Study Data  
The sponsor will make stu dy results available through www. ClinicalTrials.gov, or other public 
registries , in accordance with applicable local laws and regulations. 
Protocol  C3300-102 
 46  
    10.1.7. Data Quality Assurance 
All subject data relating to the study will be recorded on the e CRF unless transmitted to the 
sponsor or designee electronically ( eg, laboratory data). The investigator is responsible for 
verifying that data entries are accurate and correct by electronically signing the e CRF.  
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the e CRF.  
The investigator must permit study -related monitoring, audits, IRB/IEC review, and regulatory 
agency inspections and provide di rect access to source data documents.  
Monitoring details describing strategy ( eg, risk -based initiatives in operations and quality such as 
Risk Management and Mitigation Strategies and Analytical Risk -Based Monitoring), methods, 
responsibilities , and requirements, including handling of noncompliance issues and monitoring 
techniques (central, remote, or on-site monitoring) are provided in the Monitoring Plan. 
The sponsor or designee is responsible for the data management of this study including quality 
check ing of the data. 
The sponsor assumes accountability for actions delegated to other individuals ( eg, CRO s). 
Study monitors will perform ongoing source data verification to confirm that data entered into the CRF by authorized site personnel are accurate, com plete, and verifiable from source 
documents; that the safety and rights of subjects are being protected; and that the study is being 
conducted in accordance with the currently approved protocol and any other study agreements, ICH GCP, and all applicable re gulatory requirements. 
Records and documents, including signed ICFs, pertaining to the conduct of this study must be 
retained by the investigator for the longer of: 
• 2 years after the last marketing authorization for the study drug has been approved or 
the sponsor has discontinued its research with respect to the study drug, or  
• Such longer period as required by applicable US regulatory requirements or by US law 
No records may be destroyed during the retention period without the written approval of the 
sponsor. No records may be transferred to another location or party without written notification 
to the sponsor. 
10.1.8. Source Documents  
Source documents provide evidence for the existence of the subject and substantiate the integrity 
of the data collected. Source documents are filed at the investigator’s site.  
Data reported on the CRF or entered in the eCRF that are transcribed from source documents 
must be consistent with the source documents or the discrepancies must be explained. The 
investigator may need to request previous medical records or transfer records, depending on the 
study. 
Definition of what constitutes source data can be found in the Monitoring Plan. 
Description of the use of the EDC system is documented in the Data Management Plan . 
Protocol C3300-102 
47 10.1.9. Study and Site Start and Closure 
The first act of recruitment is the  date of first subject consent and will be the study start date. 
The sponsor designee reserves the right  to close the study site or terminate the study at any time 
for any reason at the sole discretion of the sponsor. The s tudy site will be closed upon study 
completion. A study site is considered closed when all required documents and study supplies 
have been collected and a study- site closure visit has been performed.  
The investigator may initiate study -site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination. 
Reasons for the early clo sure of a study site by the sponsor or investigator may include but are 
not limited to: 
•Failure of the investigator to comply with the protocol, the requirements of the
IRB/IEC or local health authorities, the sponsor's procedures, or GCP guidelines
•Inadequate recruitment of subjects by the investigator
•Discontinuation of further study intervention development
If the study is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigator, the IEC/IRB, the regulatory authorities, and any CRO(s) used in the study of the 
reason for termination or suspension, as specified by the applicable regulatory requirements. The investigator shall promptly inform the subject and should ensure appropriate subject therapy 
and/or follow -up. 
Study termination is also provided for in the clinical study agreement. If there is any conflict between the contract and this protocol, the contract will control as to termination rights.  
10.1.10. Publication Policy  
The results of this study may be published or presented at scientific meetings. The sponsor will comply with the requirements for publication of study results. Any publication of data from the study by the investigator will be subject to mutual agreement between the investigator and the 
Sponsor. 
Protocol C3300-102 
48 10.2. Appendix 2: Clinical Laboratory Tests 
All protocol -required laboratory assessment s, as defined below, must be conducted in 
accordance with the laboratory m anual and the SoA ( Table  1). 
•The laboratory  tests are detailed in  Table  2.
•Protocol- specific requirements for inclusion or exclusion of subject s are detailed in
Section  5 of the protocol.
•Additional tests may be performed at any time during the study as determined
necessary by the investigator or required by local regulations.
•The investigator may consider repeating a laboratory test for any subject who has anabnormal laboratory test result (eg, positive hemoccult test, ou t-of-range chemistry
test, abnormal urine culture) at the Discharge ( Day 8)/ET Visit . The decision to repeat
a laboratory test would be based on the investigator's clinical judgment.
Protocol  C3300-102 
 50  
    10.3. Appendix 3: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting 
10.3.1. Definition of AE and TEAE  
10.3.1.1. AE Definit ion 
• An AE is any untoward medical occurrence in a patient or clinical study subject, 
temporally associated with the use of study intervention, whether or not considered related to the study intervention.  
• NOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. 
10.3.1.2. TEAE Definition  
• A TEAE is an event that emerges, or a pre-existing event that wor sens, any time after 
the initiation of the first dosing of the investigational product. 
10.3.1.3. Events Meeting  the AE Definition  
• Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or 
other safety assessments (eg, ECG, radiological  scans, vital signs measurements), 
including those that worsen from baseline, considered clinically significant in the 
medical and scientific judgment of the investigator (ie, not related to progression of 
underlying disease). 
• Exacerbation of a chronic or intermittent pre -existing condition including either an 
increase in frequency and/or intensity of the condition. 
• New conditions detected or diagnosed after study intervention administration even 
though it may have been present before the start of the study. 
• Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction. 
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either study intervention or a concomitant medication. Overdose per se will not be reported as an AE/SAE unless it is an intentional overdose taken with possible suicidal/self-harming 
intent. Such overdoses should be reported regardless of sequelae. 
• Specific Situations  
− AEs that are secondary to other AEs:  In general, AEs that are secondary to other 
AEs (eg,  cascade events or clinical sequelae) should be identified by their primary 
cause, with the exception of severe or serious secondary events. If a medically 
significant secondary AE that is separated in time from the initiating event occurs, 
the event may be recorded as an independent event on the AE eCRF after 
consultation with the sponsor. All AEs should be recorded separately if it is not clear as to whether the events are associated.  
Protocol  C3300-102 
 51  
    − Persistent AEs:  A persistent AE is one that extends continuously, without 
resolution, between subject evaluation time points. If the severity changes 
throughout the duration of the persistent AE, record the severity as it changes. 
− Recurrent AEs:  A recurrent AE is one that resolves between subject visits and 
subsequently recurs. Each recurrence of the AE should be recorded as a separate AE on the AE eCRF.  
10.3.1.4. Events NOT Meeting the AE Definition  
• Any clinically significant abnormal laboratory findings or other abnormal safety 
assessments which are associated with the underlying disease, unless judged by the 
investigator to be more severe than expected for the subject’s condition. 
• The disease/disorder being studied or expected progression, signs, or symptoms of the 
disease/disorder being studied, unless more severe than expected for the subject’s 
condition. 
• Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that 
leads to the procedure is the AE. 
• Situations in which an untoward medical occurrence did not occur (social and/or convenience admission to a hospital). 
• Anticipated day- to-day fluctuations of pre-existing disease(s) or condition(s) present 
or detected at the start of the study that do not worsen. 
10.3.2. Definition of SAE  
If an event is not an AE per definition above (Section 10.3.1 ), then it cannot be an SAE even if 
serious conditions are met ( eg, hospitalization for signs/symptoms of the disease under study, 
death due to progression of disease). 
An SAE is defined as any untoward medical occurrence that, at any dose: 
1. Results in death  
2. Is life -threatening 
• The term “life -threatening” in the definition of “serious” refers to an event in which 
the subject was at risk of death at the time of the event. It does not refer to an event, 
which hypothetically might have caused death, if it were more severe. 
3. Requires inpatient hospitalization or prolongation of existing hospitalization  
• In general, hospitalization signifies that the subject has bee n detained (usually 
involving at least an overnight stay) at the hospital or emergency ward for 
observation and/or treatment that would not have been appropriate in the physician’s office or outpatient setting. Complications that occur during hospitalizati on are AEs. 
If a complication prolongs hospitalization or fulfills any other serious criteria, the event is serious. When in doubt as to whether “hospitalization” occurred or was necessary, the AE should be considered serious. 
Protocol  C3300-102 
 52  
    • Hospitalization for elective treatment of a pre -existing condition that did not worsen 
from baseline is not considered an AE. 
4. Results in persistent disability/incapacity  
• The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions.  
• This definition is not intended to include experiences of relatively minor medical significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma (eg, sprained ankle) which may interfere with or prevent 
everyday life f unctions but do not constitute a substantial disruption. 
5. Is a congenital anomaly/birth defect  
6. Other situations: 
• Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that may 
not be immediately life‑threatening or result in death or hospitalization but may 
jeopardize the subject or may require medical or surgical intervention to prevent one 
of the other outcomes listed in the above  definition. These events should usually be 
considered serious. 
• Examples of such events include invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalization, or development of drug dependency 
or drug abuse. 
10.3.3. Recording and Follow -up of AE and/or SAE  
10.3.3.1. AE and SAE Recording  
• When an AE/SAE occurs, it is the responsibility of the investigator to review all 
documentation (eg, hospital progress notes, laboratory reports, and diagnostics 
reports) related to the event.  
• The investigator will then record all relevant AE/SAE information in the CRF.  
• It is not acceptable for the investigator to send photocopies of the subject's medical 
records to Ironwood Global Patient Safety in lieu of completion of the SAE 
Form/AE/SAE CRF page.  
• There may be instances when copies of medical records for certain cases are 
requested by Ironwood Global Patient Safety . In this case, all subject identifiers, with 
the exception of the subject number, will be redacted on the copies of the medical 
records before submission to Ironwood Global Patient Safety.  
• The investigator will attempt to establish a  diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not the individual signs/symptoms) will be documented as the AE/SAE.  
Protocol  C3300-102 
 53  
    • For subjects who fail screening and have an SAE, only the SAE will be collected in 
CRF.  
10.3.3.2. Assessment of Intensity/Severity  
The investigator will make an assessment of intensity for each AE and SAE reported during the study and assign it to one  of the following categories, according to the NCI- CTCAE:  
• Grade  1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations 
only; intervention not indicated  
• Grade  2: Moderate; minimal, local  or noninvasive intervention indicated; limiting 
age-appropriate instrumental Activities of Daily Living (ADL) 
• Grade  3: Severe or medically significant but not immediately life -threatening; 
hospitalization or prolongation of hospitalization indicated; disa bling; limiting self-
care ADL  
• Grade  4: Life threatening consequences; urgent intervention indicated  
• Grade  5: Death related to AE  
A semicolon indicates “or” within the description of the grade.  
ADL s are defined as follows: Instrumental ADL s refer to preparing meals, shopping for 
groceries or clothes, using the telephone, managing money, etc. Self- care ADL s refer to bathing, 
dressing and undressing, feeding self, using the toilet, taking medications, and not bedridden. 
An event is defined as “serious” when it meets at least 1  of the predefined outcomes as described 
in the definition of an SAE, not  when it is rated as severe.  
10.3.3.3. Assessment of Causality  
• The investigator is obligated to assess the relationship between study intervention and 
each occurrence of each AE/SAE.  
• A “reasonable possibility” of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot be 
ruled out. 
• The investigator will use clinical judgment to d etermine the relationship.  
• Alternative causes, such as underlying disease(s), concomitant therapy, and other risk factors, as well as the temporal relationship of the event to study intervention 
administration will be considered and investigated. 
• The inves tigator will also consult IB and/or Product Information, for marketed 
products, in his/her assessment.  
• For each AE/SAE, the investigator must  document in the medical notes that he/she 
has reviewed the AE/SAE and has provided an assessment of causality.  
• There may be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to the sponsor. However, it is very 
Protocol  C3300-102 
 54  
    important that the investigator always make an assessment of causality for every 
event befor e the initial transmission of the SAE data to the sponsor.  
• The investigator may change his/her opinion of causality in light of follow-up information and send an SAE follow-up report with the updated causality assessment. 
• The causality assessment is one of  the criteria used when determining regulatory 
reporting requirements. 
10.3.3.4. Follow- up of AEs and SAEs  
• The investigator is obligated to perform or arrange for the conduct of supplemental measurements and/or evaluations as medically indicated or as requested by t he 
sponsor to elucidate the nature and/or causality of the AE or SAE as fully as possible. This may include additional laboratory tests or investigations, histopathological examinations, or consultation with other health care professionals. 
• If a subject dies during participation in the study or during a recognized follow-up period, the investigator will provide the sponsor with a copy of any postmortem findings including histopathology.  
• New or updated information will be recorded in the originally completed  CRF.  
• The investigator will submit any updated SAE data to the sponsor within 24 hours of receipt of the information.  
10.3.4. Reporting of SAEs  
10.3.4.1. SAE Reporting to Ironwood Global Patient Safety via an Electronic Data 
Collection Tool  
• The primary mechanism for reporting an SAE to the Sponsor will be the electronic 
data collection tool.  
• If the electronic system is unavailable, then the site will use the paper SAE data 
collection tool (see next section) in order to report the event within 24  hours. 
• The site will enter th e SAE data into the electronic system as soon as it becomes 
available.  
• After the study is completed, the electronic data collection tool will be taken offline 
to prevent the entry of new data or changes to existing data. 
• If the site receives a report of a  new SAE from a study subject or receives updated 
data on a previously reported SAE after the electronic data collection tool has been taken offline, then the site can report this information on a paper SAE form (see next section) or to the medical monitor /SAE coordinator by telephone. 
• Contacts for SAE reporting can be found in the study contact list. 
Protocol  C3300-102 
 55  
    10.3.4.2. SAE Reporting to Ironwood Global Patient Safety via Paper SAE Report Form 
• If the electronic data collection system is not available, email transmission of the  SAE 
report form is the preferred method to transmit this information to the medical 
monitor and SAE coordinator (ICSRoperations @ironwoodpharma.com). If email is 
not available, the SAE report form should be transmitted via facsimile.  
• In rare circumstances and in the absence of email or facsimile equipment, notification by telephone is acceptable with a copy of the SAE data collection tool sent by 
overnight mail or courier service.  
• Initial notification via telephone does not replace the need for the investig ator to 
complete and sign the SAE report form within the designated reporting time frames.  
• Contacts for SAE reporting can be found in the study contact list. 
Protocol  C3300-102 
 56  
    10.4. Appendix 4: Contraceptive Guidance and Collection of Pregnancy 
Information  
10.4.1. Definitions  
10.4.1.1. Women of Ch ildbearing Potential (WOCBP)  
A woman is considered fertile following menarche and until becoming postmenopausal unless 
permanently sterile (see below).  
If fertility is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cycle cannot be 
confirmed before first dose of study intervention, additional evaluation should be considered. 
10.4.1.2. Women Not Considered Women of Childbearing Potential  
Women in the following categories are not considered WOCBP: 
1. Premenarchal  
2. Premenopausal female with 1  of th e following: 
• Documented hysterectomy  
• Documented bilateral salpingectomy  
• Documented bilateral oophorectomy  
For individuals with permanent infertility due to an alternate medical cause other than the 
above, (eg, Mullerian  agenesis, androgen insensitivity), investigator discretion should be 
applied to determining study entry. 
Note: Documentation can come from the site personnel’s: review of the subject’s medical 
records, medical examination, or medical history interview.  
3. Postmenopausal female  
• A postmenopausal state is defined as no menses for 12  months without an alternative 
medical cause.  
• Females on hormonal replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the non-estrogen hormonal highly effective contraception methods if they wish to continue their HRT during the study. 
Otherwise, they must discontinue HRT to allow confirmation of postmenopausal 
status before study enrollment.  
10.4.2. Contracept ion Guidance  
Male subjects and female partners must use doubl e-barrier method of contraception (ie, a 
combination of male condom with either cervical cap, diaphragm, or sponge with spermicide) during the study, until after the Follow-up Phone Call on Day 21. 
Women of childbearing potential are excluded from the study. 
Protocol  C3300-102 
 57  
    10.4.2.1. Collection of Pregnancy Information 
10.4.2.1.1. Male Subjects With Partners Who  Become Pregnant  
• The investigator will attempt to collect pregnancy information on any male subject’s 
female partner who becomes pregnant while the male subject is in this study. This 
applies only to male subjects who receive study intervention. 
• After obtaining the necessary signed ICF  from the pregnant female partner directly, 
the investigator will record pregnancy information on the appropriate form and submit it to the sponsor within 24 hours of learning of the partner’s pregnancy. The 
female partner will also be followed to determine the outcome of the pregnancy. Information on the status of the mother and child will be forwarded to the sponsor. 
Generally, the follow-up will be no longer than 6 to 8 weeks following the estimated 
delivery date. Any termination of the pregnancy will be reported regardless of fetal status (presence or absence of anomalies) or indication for the procedure.  
10.4.2.1.2. Female Subjects Who Become Pregnant  
• The investigato r will collect pregnancy information on any female subject who 
becomes pregnant while participating in this study. The initial information will be recorded on the appropriate form and submitted to the sponsor within 24 hours of 
learning of a subject's pregnancy. 
• The subject will be followed to determine the outcome of the pregnancy. The 
investigator will collect follow -up information on the subject and the neonate and the 
information will be forwarded to the sponsor. Generally, follow -up will not be 
require d for longer than 6 to 8 weeks beyond the estimated delivery date. Any 
termination of pregnancy will be reported, regardless of fetal status (presence or 
absence of anomalies) or indication for the procedure. 
• While pregnancy itself is not considered to be an AE or SAE, any pregnancy 
complication or elective termination of a pregnancy for medical reasons will be 
reported as an AE or SAE. A spontaneous abortion (occurring at <22 weeks 
gestational age) or still birth (occurring at >22  weeks gestational age) is always 
considered to be an SAE and will be reported as such. Any poststudy pregnancy-
related SAE considered reasonably related to the study intervention by the 
investigator will be reported to the sponsor as described in Section 8.3.4. While the investigator is not obligated to actively seek this information in former study subjects, 
he or she may learn of an SAE through spontaneous reporting. 
• Any female subject who becomes pregnant while participating in the study be 
withdrawn from the study.  
Protocol  C3300-102 
 58  
    10.5. Appendix 5 : Abbreviations  
Table  3: List of Abbreviations  
Abbreviation Definition 
ADLs  activities of daily living  
AE adverse event  
ALT  alanine aminotransferase  
AST  aspartate aminotransferase  
AUC 0-∞ area under the plasma concentration time curve from time zero to time 
infinity  
AUC 0-t area under the plasma concentration time curve from time zero to the time at 
which the last measurable concentration is observed  
BBMD bladder and bowel movement diary  
BM bowel movement  
BMI body mass index  
BSFS Bristol Stool Form Scale  
BUN  blood urea nitrogen  
CFTR  cystic fibrosis transmembrane conductance regulator  
cGMP  cyclic guanosine monophosphate  
CIOMS Council for International Organizations of Medical Sciences  
Cmax maximum plasma concentration  
CONSORT  Consolidated Standards of Reporting Trials  
CRO contract research organization  
CRP c-reactive protein  
CRU clinical research unit  
CV%  coefficient of variation  
DMC  data monitoring committee  
DR delayed release  
eCRF electronic case report form  
EDC  electronic data capture  
ESR erythrocyte sedimentation rate  
ET early termination  
FSH follicle -stimulating hormone  
GC-C guanylate cyclase C  
Protocol  C3300-102 
 59  
    Abbreviation Definition 
GI gastrointestinal 
HBsAg  hepatitis B surface antigen  
HCV  hepatitis C virus  
HCG  human chorionic gonadotropin  
HED  human equivalent dose  
HEENT  head, eyes, ears, nose, and throat 
HIPAA  Health Insurance Portability and Accountability Act  
HIV human immunodeficiency virus  
HRT  hormonal replacement therapy 
IB investigator’s brochure  
IBS-C irritable bowel syndrome with constipation  
IBS-D irritable bowel syndrome with diarrhea  
IC/BPS interstitial cystitis /bladder pain syndrome  
ICF informed consent form  
IEC independent  ethics committee  
IMP investigational medical product  
INR international normalized ratio  
IRB institutional review board 
LLOQ  lower limit of quantitation  
MCH mean corpuscular hemoglobin  
MCHC  mean corpuscular hemoglobin concentration  
MCV mean corpuscular volume  
MedDRA  Medical Dictionary for Regulatory Activities  
MRP multidrug resistance protein  
NCI-CTCAE  National Cancer Institute Common Terminology Criteria for Adverse Events  
NIMP  noninvestigational medical product  
NOAEL  no-observed -adverse-effect level 
PK pharmacokinetic(s)  
PKGII  protein kinase G type II  
RBC red blood cell  
SAE  serious adverse event  
SAP statistical analysis plan  
Protocol  C3300-102 
 60  
    Abbreviation Definition 
SARS ‑CoV ‑2 severe acute respiratory syndrome coronavirus 2  
SID subject identification 
SoA schedule of activities 
SUSAR  suspected unexpected serious adverse reaction 
t1/2 terminal elimination half -life 
TBD to be determined  
TEAE treatment-emergent adverse event 
TESAE treatment-emergent serious adverse event 
Tmax time to maximum plasma concentration  
UA urinalysis  
ULN  upper limit of normal  
WBC white blood cell  
WOCBP woman/women of childbearing potential  
Protocol  C3300-102 
 61  
    10.6. Appendix 6 : Protocol Signatures  
10.6.1. Sponsor Signature  
Protocol Title:  A Phase 1 Placebo -controlled Study of the Safety and 
Tolerability of Rectally Administered, Multiple -ascending 
Doses of IW -3300 in Healthy Subjects 
Short Title:  A Phase 1 Study of Multiple- ascending Doses of IW-3300 in 
Healthy Subjects  
Protocol Number:  C3300-102 
Version Number:  Version 1 
Final Date:  14 February 2022 
This clinical study protocol was subject to critical review and has been approv ed by the sponsor. 
 
  
{Electronic signature page  appended}   
  
Head of Clinical Development and Medical 
Scientific Affairs  
Ironwood Pharmaceuticals, Inc.  Date  

Protocol  C3300-102 
 62  
    10.6.2. Investigator Signature  
Protocol Title:  A Phase 1 Placebo -controlled Study of the Safety and 
Tolerability of Rectally Administered, Multiple -ascending 
Doses of IW -3300 in Healthy Subjects 
Short Title:  A Phase 1 Study of Multiple- ascending Doses of IW-3300 in 
Healthy Subjects  
Protocol Number:  C3300-102 
Version Number:  Version 1 
Final Date:  14 February 2022 
I have read the protocol described above. I agree to comply with all applicable regulations and to 
conduct the study as described in the protocol. 
Investigator Name:  
  
 
Signed:  
 Date:   
Protocol  C3300-102 
 63  
    11. REFERENCES  
1. Castro J, Harrington AM, Hughes PA, Martin CM, Ge P, Shea CM, et al. Linaclotide 
Inhibits Colonic Nociceptors and Relieves Abdominal Pain via Guanylate Cyclase-C and 
Extracellular Cyclic GMP. Gastroenterology. 2013;145(6):1334‑ 46. 
2. Grundy L, Harrington AM, Castro J, Garcia-Caraballo S, Deiteren A, Maddern J, et al. 
Chronic linaclotide treatment reduces colitis -induced neuroplasticity and reverses 
persistent bladder dysfunction. JCI Insight. 2018;3(19):e121841. 
3. Pfeifer A, Aszódi A, Seidler U, Ruth P, Hofmann F, Fässler R. Intestinal secretory defects and dwarfism in mice lacking cGMP -dependent protein kinase II. Science. 
1996;274(5295):2082‑ 6. 
4. Forte, LR. Uroguanylin and guanylin peptides: pharmacology and experimental 
therapeutics. Pharmacol Ther. 2004;104(2):137 ‑62. 
5. Schlossmann J, Feil R, Hofmann F. Insights into cGMP signalling derived from cGMP 
kinase knockout mice. Frontiers in Bioscience. 2005;10:1279 ‑89. 
6. Forte LR. Guanylin regu latory peptides: structures, biological activities mediated by 
cyclic GMP and pathobiology. Regul Pept. 1999;81(1‑ 3):25‑39. 
7. London RM, Krause WJ, Fan X, Eber SL, Forte LR. Signal transduction pathways via 
guanylin and uroguanylin in stomach and intestine. Am J Physiol. 1997;273(1 Pt 1):G9 3‑105. 
8. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol. 1997;32(9):920 ‑4. 
 
The data and information in this file that pertain to my line function are 
truthful and accurate.
Signature Page for VV-CLIN-004845 
v1.0Approval
23-Feb-2022 22:11:16 GMT+0000
